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Abstract: Before 2010, the Federal Aviation Administration (FAA) did not allow airmen 
to exercise the privileges of pilot in command (PIC) of an aircraft or obtain a medical 
certificate if one had been diagnosed with anxiety, depression, and/or taking an SSRI 
medication.  Since 2010, the FAA has relaxed its views and certification standards.  
However, this is not an issue unique to the United States.  The International Civil 
Aviation Organization (ICAO) and other ICAO States began looking at these issues in 
early 2000.  ICAO and most ICAO States have identified the need for further research 
regarding mood disorders and airmen.  In addition, ICAO has issued guidance regarding 
certification standards, though each ICAO State has the authority to set its own standards.  
While the FAA and the other ICAO States have accepted mood disorders in aviation as a 
reality, much is additional work is needed to unify standards within the international 
community.  States which have more stringent standards may force airmen to seek 
alternative treatment options and not disclose crucial medical information or seek 
appropriate treatment options in fear of reprisal.  
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The topic of pilots and mental health is a sensitive issue.  Moreover, the Federal Aviation 
Administration (FAA) has maintained strict guidelines that prevented pilots from exercising the 
privileges of any license or obtaining a medical certificate for those suffering from, or diagnosed 
with, anxiety, depression, and/or taking a selective serotonin reuptake inhibitor (SSRI).  The 
federal regulations regarding mental health in pilots and the use of SSRIs are maintained in the 
Code of Federal Regulations 14 CFR Part 67: Medical Standards and Certification (GPO, n.d.).  
According to the FAA, since 2010 the agency has relaxed some of its requirements allowing 
pilots to use certain SSRIs under issuance of a medical waiver (FAA, 2010a). 
Background of the Study 
Currently, the FAA approves four SSRI medications for pilot use: (1) Lexapro; (2) 
Prozac; (3) Celexa; and (4) Zoloft (FAA, 2017b).  Applicants are required to indicate on their 
medical application if they are taking an SSRI, and whether one has been diagnosed with or has a 
history of anxiety or depression (FAA, 2017b).  An aviation medical examiner (AME) is 
instructed not to issue a medical certificate (under most cases) and submit the application to the 
FAA for further review (FAA, 2017b).  
After a pilot has submitted a medical application, that individual must be monitored and 
re-evaluated after six months of a consistent single-dose usage of one of the four FAA approved
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medications (FAA, 2017b).  Initial evaluations and pilot monitoring are conducted by an 
appropriate mental health specialist (e.g., psychiatrist).  After completion of a six-month 
demonstration period, a pilot may request a re-evaluation from their psychiatric care physician 
(FAA, 2017b).  A statement from the treating physician should indicate that the pilot does not 
display any adverse side effects to the medication and the treatment option is stabilizing the 
individual’s mood (FAA, 2017b).  A specialist from the FAA Aeromedical Division will evaluate 
the documentation and grant or deny the request for a medical waiver (FAA, 2017b).  
While the certification process was initially lengthy, it has been shortened in recent years 
(FAA, 2010a).  Initially the medical waiver process required pilots to demonstrate 12 months of 
consistent SSRI use along with appropriate documentation; however, even with a recent reduction 
to a six-month evaluation period, there is no guarantee that a medical waiver will be granted 
(FAA, 2017b).  In addition, while the FAA has allowed the use of some medications, they still 
prohibit most SSRIs and other mood-altering medications (FAA, 2017b).   
Generalized anxiety disorder (GAD) and depression are among the most common mood 
disorders in the U.S. (ADAA, 2016).  While there are several sub-categories of each disorder, 
approximately 6.7 million Americans suffer from GAD, and approximately 15 million are 
diagnosed with depression (ADAA, 2016).  Events that trigger these disorders can be widespread 
which can be affected by genetics, stress, social makeup, phobias, and traumatic experiences 
(ADAA, 2016).  The Anxiety and Depression Association of America (ADAA) states that most 
adults will experience some form of anxiety or depression in their lives (ADAA, 2016). 
Approximately 80% of individuals who suffer from one of these disorders never seek 
diagnosis, and some individuals who are diagnosed never seek treatment options (Healthline, 
2017).  Transport Canada has concluded that approximately 6% of the population suffers from 
some form of mood disorder (Transport Canada, 2018b).  Furthermore, this same ratio exists 
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among the pilot population (Transport Canada, 2018b).  A standard treatment option for those 
suffering from anxiety or depression is to prescribe those individuals with a selective serotonin 
reuptake inhibitor (SSRI) (ADAA, 2016).  SSRIs work by altering the chemical makeup of the 
brain; changing how serotonin interacts within the neurotransmitters and how messages are sent and 
received (ADAA, 2016).  Approximately 80% to 90% of individuals who are prescribed an SSRI for 
mood disorders have positive results with the treatment and experience few side effects (ADAA, 
2016).  
Statement of the Problem 
During the past several decades the Federal Aviation Administration (FAA) has strictly 
prohibited the use of SSRI medications (FAA, 2010a).  Any pilot who had been diagnosed with 
or has symptoms of anxiety, depression, and/or taking an SSRI were prohibited from exercising 
the privileges of an airman certificate and obtaining any class of FAA medical (FAA, 2010a).  
Pilots who had been prescribed an SSRI in the past were required to demonstrate a successful 
discontinued use of the medication for at least 90 days before consideration of a medical 
certificate was granted (FAA, 2010a).   
The International Civil Aviation Organization (ICAO) and many of its member States 
have a different approach to SSRI medications and airmen medical certification.  Australia, for 
example, has conducted studies regarding mood disorders, SSRIs, and other treatment options as 
early as the 1980s and has since approved their pilots to take these medications and retain flight 
status (Werfelman, 2008).  One requirement has been that the pilots must receive awareness 
training regarding the effects of anxiety and depression as well as demonstrate the ability to 
recognize symptoms associated with these disorders (Werfelman, 2008).  In addition to awareness 
training, Australian pilots must successfully pass their medical examination (Werfelman, 2008).  
Pilots must also demonstrate they have successfully taken an SSRI for at least four weeks with no 
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adverse side effects, and they may be required to complete status reports once every six months 
(Werfelman, 2008).  The Civil Aviation Safety Authority (CASA) of Australia has concluded that 
pilots taking an SSRI pose no significant safety threat when compared to individuals who do not 
suffer from a mood disorder (Nowak, 2007). 
It should be noted that while the FAA has relaxed its certification standards and views on 
the topic, there are many questions and potential problems still prevalent.  Some of these 
questions or problems include: (1) pilot compliance with FAA standards; (2) pilots not seeking 
help when needed; (3) pilots seeking unauthorized treatment options; (4) how FAA views align 
with ICAO and other ICAO States; and (5) the SSRI medications currently approved by the FAA.  
Dr. Lacy Anderson (2018) has noted that not all SSRI medications are the same.   Moreover, 
some patients respond better to some SSRIs than others (L. Anderson, personal communication, 
July 16, 2018).  Currently, the FAA only approves four SSRI medications: (1) Lexapro; (2) 
Prozac; (3) Celexa; and (4) Zoloft (FAA, 2017b).  However, there are many other SSRIs on the 
market such as Paxil, norepinephrine-dopamine reuptake inhibitors (NDRIs) such as Wellbutrin, 
serotonin and norepinephrine reuptake inhibitors (SNRIs) such as Cymbalta, or next generation 
medications such as Buspar (L. Anderson, personal communication, July 16, 2018).  Many of 
these medications may work better for one individual over another (L. Anderson, personal 
communication, July 16, 2018).  While the FAA may slowly be aligning their views with ICAO 
and the international community, past and current views may cause a stagnation point and 
confusion for pilots regarding the appropriate course of action.  Social stigmas may also alter a 
pilot’s ability to make sound decisions regarding obtaining a medical diagnosis, exploring 





Purpose and Significance of the Study 
The purpose of this research study was two-fold.  The findings from the study should 
help conclude whether the FAA’s viewpoints regarding mood disorders and treatment options are 
too stringent or outdated when compared to recommendations by ICAO and the medical 
certification standards of other ICAO States.  In addition, the responses from the participating 
U.S. pilot group should help identify how familiar they are with FAA views regarding mood 
disorders and SSRI use in airmen, as well as indicate whether current FAA medical certification 
standards for mood disorders and SSRI use are beneficial to the U.S. pilot population. 
This international research study will be significant because anxiety and depression are 
common mood disorders among the pilot population (Stoutt, n.d.; Transport Canada, 2018b).  It is 
the researcher’s opinion that further information on the subject is necessary.  It is also the opinion 
of the researcher that only a few studies regarding U.S. pilots and the use of SSRI medications 
have been conducted compared to the more significant number of SSRI research studies 
completed within the international community and their pilot populations.  The findings from this 
study may assist in determining if current FAA certification standards are too stringent, and how 
those standards affect pilots suffering from these disorders.  The findings will provide additional 
information for both the FAA and the aviation community on the subject of pilots and SSRI 
medications that have may not been previously considered or publicly shared in the literature. 
Research Questions 
The following research questions were developed to align with the intent of this study:  
RQ1 - Are the FAA’s certification standards for pilots suffering from anxiety and/or 
depressive disorders too stringent, limited, or outdated when compared to ICAO 
or other ICAO States? 
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RQ2 - Are the FAA’s certification standards for pilots taking SSRIs as a treatment option 
for anxiety and/or depressive disorders too stringent, limited, or outdated when 
compared to ICAO or other ICAO States? 
RQ3 - Can medical professionals outside the FAA provide additional support regarding 
the adequacy or inadequacy of pilot certification standards for those suffering 
from anxiety, depression, or who are using SSRIs? 
RQ4 - How does the U.S. pilot population view FAA certification standards on the 
subject of SSRIs, anxiety, and depressive disorders? 
Assumptions and Limitations 
The researcher acknowledged certain limitations and assumptions of this study and 
maintained full consideration for ensuring objectivity, reliability, and validity.  Potential 
limitations and assumptions in this study include: 
1. The data gathered by the researcher will be limited by the actual number of 
participants that volunteer to complete the research questionnaire and the personal 
interviews. 
2. The amount of information the FAA, ICAO, and ICAO States may be willing to 
share regarding the subject. 
3. The FAA, ICAO, and ICAO State employees’ professional knowledge on the subject 
matter. 
4. The number of published research studies regarding pilot use of SSRI medications. 
5. If the participant will answer the questionnaire or interview questions honestly and 
without any influence; actual or perceived. 
6. Due to time constraints, some participants may be unable to provide phone interviews 
but rather communicate in writing. 
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Definition of Terms 
The following definitions have been included to promote familiarity with terms used 
commonly throughout this study. 
Aerospace Medical Association (AsMA).  The Aerospace Medical Association (AsMA) is an 
organization created to educate and contribute scientific information regarding human 
performance, aviation medical standards, physiology of human flight, and aviation medicine.  It is 
the largest professional organization with the most representation in this field. Approximately 
30% of its members are within the international community.  Industry specialists include 
physicians, physician’s assistants, flight nurses, human factors specialists, psychologists, and 
other industry specialists (AsMA, n.d.).  
American Psychological Association (APA).  The APA is noted as being a leading professional, 
and scientific organization represents the field of psychology in the U.S.  The organization 
encompasses over 100,000 educators, researchers, consultants, clinicians, and students who make 
up its members (APA, n.d.a). 
Anxiety.  Anxiety is an emotion that may be characterized by several feelings. These can include 
worried thoughts, increased feeling of tension, and intrusive thoughts. Physical characteristics 
such as increased blood pressure, trembling, sweating, dizziness, and increase heart rates may 
also be prevalent (APA, n.d.b). 
Civil Aviation Authority (CAA) UK). The Civil Aviation Authority of the UK was established 
in 1972 as the regulatory body for civil aviation.  In addition to promoting safety and consumer 
protection, the agency also has oversight for many facets in the industry which includes airman 
certification, medical standards, manufacturing and maintenance operations, flight operations, 
flight schools, and training and education (CAA UK, n.d.). 
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Civil Aviation Safety Authority of Australia (CASA).  The Civil Aviation Safety Authority 
was established in 1995 and is the agency responsible for safety and civil aviation regulations in 
Australia.  The agency works in conjunction with the Australian Transport Safety Bureau and has 
oversight for many facets in the industry which includes airman certification, medical standards, 
manufacturing and maintenance operations, flight operations, flight schools, and training and 
education (CASA, 2018). 
Code of Federal Regulations (CFR).  The Code of Federal Regulations refers to regulations 
published in the Federal register by various departments and agencies for the federal government. 
Reference to these regulations in this research study will refer to those about aviation regulations 
(GPO, n.d.).  
Depression.  The most common of mental disorders.  Often the disorder is associated with a lack 
of interest or pleasure in normal activities. Physical symptoms may induce a lack of energy, 
feelings of guilt or worthlessness, insomnia or excessive sleeping and weight gain or loss.  
Recurring thoughts of death or suicide may also be present (APA, n.d.c). 
Federal Aviation Administration (FAA).  The Federal Administration made the change from a 
government agency in 1967 to carry out regulatory programs and policies in civil aviation. The 
FAA’s mission, aside from aviation regulation, is to, “Provide the safest, most efficient aerospace 
system in the word”.  The FAA has oversight for many facets in the industry which includes 
airman certification, medical standards, manufacturing and maintenance operations, flight 
operations, flight schools, and training and education (FAA, n.d.b). 
Federal Aviation Regulations (FAR).  The Federal Aviation Regulations are a subsection of the 
Code of Federal Regulations under Title 14: Aeronautics and Airspace (GPO, n.d.). 
International Civil Aviation Organization (ICAO).  The International Aviation Organization 
was established in 1944 and consists of 192 member States.  States (or countries) work to 
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establish uniformity and standardization in aviation worldwide.  Their focus is on safety, 
responsibility, technology, efficiency, environmental concerns within the aviation community 
(ICAO, n.d.). 
Luftfahrt-Bundesamt (LBA).  The Luftfahrt-Bundesamt was established in 1954.  The Federal 
Aviation Office division of the organization is given authority for civil aviation regulatory 
oversight throughout Germany.  The agency is comprised of several divisions that range from 
safety, security, operations, and administration. In addition to rules and regulations, the agency 
has oversight regarding airman certification, manufacturing and maintenance operations, medical 
certification, flight schools, and training and evaluations (LBA, 2014).  
Mood Disorder.  Class of mental health disorder to describe on a broad scale all forms of bipolar 
disorders and depression.  Conditions are not limited to adults and may include teens and children 
as well.  However, children and teens are often more challenging to diagnose as they are not as 
effective at commutating feelings and emotions as adults.  Mover, symptoms may differ from 
those of adults (Johns Hopkins Medical, n.d.). 
Norepinephrine-Dopamine Reuptake Inhibitor (NDRI).  A class of drug used to treat 
depression.  May also be used as a smoking cessation aid. NDRIs work by prohibiting the 
reuptake inhibition of norepinephrine and dopamine.  It may also control the release of the 
substance within the nerve cells (Pharmacology Institute, n.d.). 
Selective Serotonin Reuptake Inhibitor (SSRI).  A class of drug used to treat depression.  
SSRIs work by slowing the process of reusing serotonin by the nerve cells that make the 
substance.  This process allows for increased availability of serotonin for nerve stimulation 
(National Cancer Institute, n.d.c).  
Serotonin and Norepinephrine Reuptake Inhibitor (SNRI).  A type of drug that increases 
levels of serotonin and norepinephrine in the brain.  Used to treat depression and other disorders.  
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Both substances act as a neurotransmitter which allows nerves to send and receive messages 
between one another (National Cancer Institute, n.d.a). 
Serotonin.  A hormone found in the brain, glands, and other areas of the body.  Serotonin acts as 
a neurotransmitter which allows nerves to send and receive messages between one another 
(National Cancer Institute, n.d.b). 
Swedish Transport Agency (STA). The Swedish Transport Agency was established in 2009 and 
comprises of multiple division which governs multiple modes of transpiration.  The Civil 
Aviation and Maritime division are charged with the regulation of civil aviation.  The division 
also has oversight for many facets in the industry which includes airman certification, medical 
standards, manufacturing and maintenance operations, flight operations, flight schools, and 
training and education (STA, n.d.). 
The Directorate General for Civil Aviation (DGAC). The Directorate General for Civil 
Aviation includes the French Civil Aviation Authority division. Aside from being the regulatory 
civil aviation authority for France, the agency focuses on safety and security, environmental 
issues, and development of civil air transportation. The division also has oversight for many 
facets in the industry which includes airman certification, medical standards, manufacturing and 
maintenance operations, flight operations, flight schools, and training and education (DGAC, 
n.d.). 
Transport Canada.  Transport Canada is the governing authority which is responsible for 
Canadian transportation policies and programs.  The mission or the agency is to promote 
environmentally-responsible transportation while ensuring efficiency, safety, and security 







The purpose of this research study was two-fold.  The findings from the study should 
help conclude whether the FAA’s viewpoints regarding mood disorders and treatment options are 
too stringent or outdated when compared to recommendations by ICAO and the medical 
certification standards of other ICAO States.  In addition, the responses from the participating 
U.S. pilot group should help identify how familiar they are with FAA views regarding mood 
disorders and SSRI use in airmen, as well as indicate whether current FAA medical certification 
standards for mood disorders and SSRI use are beneficial to the U.S. pilot population. 
This chapter provides an overview of the existing body of literature related to: 
1. Pilots and Mental Health;  
2. Side Effects Associated with SSRIs;  
3. Anxiety, Depression, SSRIs, and Aviation-Related Accidents;  
4. Public Perception of Pilots;  
5. The FAA’s Airmen Medical Certification Process;  
6. BasicMed;  
7. ICAO, ICAO States, and the Medical Certification Process;  
8. Current U.S. Research Regarding Pilot Compliance;  
9. Alternative Treatment Options; and  
10. Research Promoting Regulatory Change in Treatment Options for Pilots.
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An analysis of the reviewed literature regarding the subject of pilots and SSRI medications 
revealed common themes that substantiated the importance of exploring the research questions of 
this study. 
Pilots and Mental Health 
It is estimated that between 10 and 20 million people in the U.S. suffer from some form 
of anxiety or depression (Stoutt, n.d.).  Approximately one in ten men and one in four women will 
be affected by anxiety or depression at some point in their life.  These disorders have become so 
common that they are often referred to as the common cold of psychiatry (Stoutt, n.d.).  It is no 
surprise that pilots are also affected by these mental disorders as well (Stoutt, n.d.).   
Often anxiety is associated with intense bouts of fear (Lott, & Stenson, n.d.).  These 
feelings or threats may be real or imaginary (Lott, & Stenson, n.d.).  Often these fears may trigger 
a reactive response in the form of a panic attack which can be debilitating depending on the 
severity (Lott, & Stenson, n.d.).  Some symptoms of anxiety include excessive worrying, trouble 
sleeping, headaches, stomach aches, and vomiting.  These symptoms may cause an individual to 
avoid certain situations or develop phobias that may interfere with daily life, work, academics, or 
other social settings (Lott, & Stenson, n.d.).  In some cases, pilots have even developed a fear of 
flying (Bor, Field, & Scragg, 2002). 
Depression, the second most common mood disorder, can become more detrimental to 
pilots due to its potentially debilitating effects (FSF, 2001).  Depression may be progressive 
throughout a person’s day, and symptoms may become more prevalent (Stoutt, n.d.).  Many 
symptoms of depression include periods of sadness, grief, fatigue, and loss of interest in normal 
activities (Stoutt, n.d.).  Moreover, a person may experience loss of appetite, irritability, 
irrationalism, and even feelings of guilt (Stoutt, n.d.).  Depression may also be classified as a 
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form of bipolar disorder (often referred to as manic depression) (FSF, 2001).  Symptoms include 
alternating periods of mania and bouts of depression (FSF, 2001).   
Not all mental health issues or psychological problems are easily detectable (Bor, Field, 
& Scragg, 2002).  Some symptoms may lay dormant in an individual for years (Bor, Field, & 
Scragg, 2002).  Moreover, some symptoms are difficult for mental health professionals to 
simulate during a professional assessment (Bor, Field, & Scragg, 2002).  Therefore, it is not 
reasonable to expect that flight crew members will always be self-aware of underlying problems 
and they may often rely on a family member or coworker observations (Bor, Field, & Scragg, 
2002).  Many mental health and personality disorders remain undiagnosed until the individual 
shows long-term and repeated behaviors that can make it difficult to work or cooperate with 
others (Bor, Field, & Scragg, 2002).  The U.S. airline industry, for example, requires pilots to be 
displaced from their home environment for extended periods of time (Bor, Field, & Scragg, 
2002).  This may create a dissociation with close relationships that can further affect the pilot’s 
overall mental performance (Bor, Field, & Scragg, 2002).  However, a stable and productive 
home life with strong personal relationships may be able to act as a buffer between added work-
related stress (Bor, Field, & Scragg, 2002).   
The discontinuity in work schedules, a displaced home life, and a high mental demand in 
the cockpit are not be the only contributing factors to stress-related health issues (Manford et al., 
2016).  In some cases, noise can also be a contributing factor (Manford et al., 2016).  Studies 
have concluded that noise is an environmental stressor which can have adverse effects on 
physical health including a decrease in sleep, heart failure, arrhythmia, and development of 
hypertension issues (Manford et al., 2016).  However, the overall effects of noise on mental 
health have not been studied extensively (Manford et al., 2016).  The flight environment is a 
noisy atmosphere (Manford et al., 2016).  The researcher also that notes based on professional 
experience, the type of aircraft flown or the mission itself can determine the amount of noise a 
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pilot is exposed to during normal working conditions. This is another reason why additional 
research studies are needed to determine if the effects of noise can contribute to an increased level 
of anxiety or depression in pilots and flight crews (Manford et al., 2016).  
Side Effects Associated with SSRIs 
According to the Flight Safety Foundation (2001), SSRIs are relatively new regarding 
antidepressant medication.  They are a popular choice for prescribers as they often have limited 
side effects.  However, some of the side effects that may be associated with antidepressants 
include dry mouth, elevated heart rate, blurred vision, confusion, and sexual dysfunction (FSF, 
2001; Ireland, 2002).  While SSRIs are commonly used to treat both anxiety and depression, 
those suffering from anxiety often require higher doses of SSRI medication than those taking 
similar medication for managing depression (Ireland, 2002).  This often elevates the potential for 
an increase of unwanted side effects (Ireland, 2002). 
In a 2007 report, Canadian Forces airmen were allowed to regain flight status after 
undergoing treatment for depression and a six-month observation period overseen by an aviation 
psychiatrist.  During the study, airmen reported an increase in fatigue and sleepiness; however, it 
was determined that their symptoms did not affect their overall job performance.  The study 
concluded that while some popular SSRIs had no impact on psychomotor tasks, airmen did 
display some of the expected side effects including insomnia, fatigue, and tremors.  Nonetheless, 
aircrews taking SSRI medication were allowed to return to flight duty with restrictions (Paul, 
Gray, Love, & Lange, 2007).  
In 2003 a study was conducted evaluating the modulation of sleep in those taking an 
SSRI.  During a five-week period, SSRI medication was found to be associated with insomnia 
(Nicholson, 2003).  In many cases, research subjects reported difficulty in falling asleep and an 
increase in the number of awakenings throughout the night (Nicholson, 2003).  Some subjects 
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also reported difficulty in falling back asleep (Nicholson, 2003).  However, in some cases where 
subjects reported an increase in drowsiness, the same subjects prescribed an SSRI demonstrated 
an improvement in performance with enhanced alertness (Nicholson, 2003).  Researchers have 
concluded there is still a lack of understanding between aviation and the pharmacological effects 
of antidepressants on higher level skills (Nicholson, 2003).  In addition, not enough evidence 
exists to fully understand whether a given medication will be safe for use by a pilot (Nicolson, 
2003).  To make more informed decisions multiple disciplines may need to work together to 
develop conclusions and recommendations when addressing aerospace medicine and 
psychological medications (Nicholson, 2003).  
Regardless of intended use, all SSRI medication used by pilots must be evaluated 
carefully (Ireland, 2002).  Monitoring pilot performance is necessary to ensure any symptoms 
experienced from medication pose a minimal threat to flight safety without the possibility of 
sudden pilot incapacitation (Ireland, 2002).  While new generation SSRIs have fewer side effects, 
there have been recorded cases of incapacitating side effects in some pilots (Ireland, 2002). 
Anxiety, Depression, SSRIs, and Aviation-Related Accidents 
Egypt Air Flight 990 
In 1999, Egypt Air flight 990, a Boeing 767, crashed from what experts believed to be an 
intentional act (NTSB, 2002).  A National Transportation Safety Board (NTSB) investigation 
(2002) concluded the crash resulted from a series of unexplained and contributing events.  At one 
point during the flight, the captain left the cockpit leaving the first officer alone at the controls.  
The flight data recorder (FDR) indicated the first officer reduced both thrust levers to idle, 
switched the engine controls from the run to off position, and pitched the nose down.  The first 
officer stated, “I rely on God” as heard on the cockpit voice recorder (NTSB, 2002). 
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The NTSB report (2002) indicated the captain re-entered the cockpit and questioned the 
first officer; however, the first officer did not acknowledge.  At some point, the captain attempted 
to pull the plane out of the dive.  The FDR indicated that while the captain’s control column was 
full aft (indicating an attempt to arrest the descent), the first officer’s control column was full 
forward (indicating an attempt to keep the aircraft in a dive).  The aircraft broke apart due to 
excessive stress and all 217 people on board perished.  While the motivations of the first officer 
are not understood, the NTSB concluded that at one point during the flight the airplane was in a 
recoverable position.  The Egyptian government will not conclude that the accident was the result 
of pilot suicide, but rather due to mechanical malfunctions.  However, the NTSB concluded the 
probable cause of the crash was the result of the first officer’s relief of control inputs (NTSB, 
2002).   
FedEx Flight 705 
In 1994, FedEx Flight 705 declared an emergency after Auburn Calloway, a company 
employee, entered the cockpit and attacked crew members with a hammer (United States v. 
Calloway, 1997).  At one point the assailant left the cockpit and returned with a spear gun (United 
States v. Calloway, 1997).  Two flight crew members were able to fend off the assailant while the 
captain returned to the airport for an emergency landing (United States v. Calloway, 1997).  All 
crew members received serious injury during the attack (United States v. Calloway, 1997).  
An investigation uncovered that Mr. Calloway was facing job termination and had 
substantial financial obligations (Price & Forrest, 2016).  Speculations indicated that he intended 
to crash the plane into FedEx headquarters (Price & Forrest, 2016).  Before the incident, Mr. 
Calloway made several financial transactions which included sending two cashier’s checks, one 
for $14,000 and another $40,000 to his ex-wife, and he changed his life insurance policy 
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beneficiaries (United States v. Calloway, 1997).  At his trial, Mr. Calloway plead not guilty due 
to temporary insanity (Price & Forrest, 2016). 
Boeing 737-338ER 
In 2005, the Australian Transport Safety Bureau (ATSB) investigated the precautionary 
landing of a Boeing 737-338ER jetliner.  The flight was an international operation carrying 
passengers from Auckland to Melbourne.  Investigative reports indicated that the pilot in 
command (PIC) showed signs of shakiness, fatigue, and nausea while en route to Melbourne, and 
flight crew members provided him with supplemental oxygen.  He was later relieved of 
command, and the flight landed as a precaution.  The pilot was taken to a local hospital for 
observation; however, tests were inconclusive (ATSB, 2006).  
An examination of the pilot’s medical records indicated a history of anxiety and other 
stress-related health issues (ATSB, 2006).  The pilot had been prescribed an SSRI for stress and 
was undergoing stress management treatments (ATSB, 2006).  The ATSB indicated that the pilot 
also had a history of hypertension (ATSB, 2006).  While medical tests were inconclusive, the 
ATSB stated it was possible the PIC’s incapacitation was a result of low blood pressure combined 
with an anxiety attack which led to fatigue (ATSB, 2006).  After the incident, the pilot reported 
that his stress-related issues were due to many unstructured life events as well as his home life 
(ATSB, 2006).  The Civil Aviation Safety Authority (CASA) of Australia indicated the agency 
was aware of the pilot’s condition, his treatment, and that the pilot was consistently monitored to 
ensure compliance with medical certification standards (ATSB, 2006).  
Germanwings 9525 
In 2015, the case of Germanwings 9525 gained wide-spread international media coverage 
after the plane crashed due to what the French Bureau d’Enquêtes et d’Analyses (BEA) 
determined to be, “Deliberate and planned action of the copilot, who decided to commit suicide 
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while alone in the cockpit” (FSF, 2016, para 1).  An investigation uncovered that the first officer 
(copilot) had been taking unapproved prescription medication for mental health issues, and the 
medication had caused adverse side effects (FSF, 2016).  The investigation also uncovered that a 
general care physician had recommended additional psychiatric care and hospitalization for the 
first officer (FSF, 2016).  Reports also indicated he had been previously diagnosed with psychosis 
(FSF, 2016).  
According to a 2016 Flight Safety Foundation (FSF) report, the unapproved medications 
consumed by the first officer were found to be a combination of antidepressants and sleeping 
aids.  Despite the findings and concerns, there was no apparent notification from healthcare 
providers to any aviation authority alerting them to the medical status of the pilot.  As a result, the 
BEA made recommendations to legislators to mandate revised regulations that will balance the 
fine line between public safety and an individual’s right to medical privacy.  The Flight Safety 
Foundation made the following public statement: 
It’s disturbing to learn that the Germanwings copilot was taking prescription 
antidepressant medications with possible significant side effects, and that a doctor just 
weeks before this tragedy had recommended psychiatric hospital treatment, but neither 
the pilot’s employer nor the regulator were informed. We need to find better ways to 
encourage pilots and other safety professionals to come forward to obtain treatment for 
mental health issues without jeopardizing their jobs, but it’s unacceptable to keep their 
employers and regulators in the dark, and the traveling public at risk (FSF, 2016, para 2). 
U.S. General Aviation Accident Studies 
In 2007, a research study was conducted that evaluated SSRI usage in pilots and accident 
rates in the U.S.  Between 1990-2001 there were 61 fatal aviation accidents where SSRIs were 
found in the pilot’s blood system (Sen, Akin, Canfield, & Chaturvedi, 2007).  Of the 61 pilots 
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studied, 59 had medical records in the FAA’s Medical Certification Database while two of the 
pilots did not have medical records on file (Sen, Akin, Canfield, & Chaturvedi, 2007).  Previous 
incidents of driving while under the influence were reported by 22 of the 59 pilots (Sen, Akin, 
Canfield, & Chaturvedi, 2007).  Seven of the 61 of the pilots disclosed psychological problems on 
previous medical applications that were subject for disqualification (Sen, Akin, Canfield, & 
Chaturvedi, 2007).  Of those seven pilots, three reported using an SSRI (Sen, Akin, Canfield, & 
Chaturvedi, 2007). 
At the time of the study, researchers noted that newer generation antidepressants were 
being developed that were more effective at treating anxiety and depression than older generation 
antidepressants (Sen, Akin, Canfield, & Chaturvedi, 2007).  However, at the time of the study the 
FAA did not approve SSRIs for use despite research findings (Sen, Akin, Canfield, & Chaturvedi, 
2007).  Out of the 61 cases studied, 12 pilots were found to have a medical history of SSRI usage 
with a previous diagnosis of psychological conditions or psychiatric disorders (Sen, Akin, 
Canfield, & Chaturvedi, 2007).   In two of these cases, the conditions and disorders were reported 
to the Civil Aerospace Medical Institute (CAMI) (Sen, Akin, Canfield, & Chaturvedi, 2007). 
Most of the pilots in this research study held a private pilot certificate with a third-class 
medical (Sen, Akin, Canfield, & Chaturvedi, 2007).  Approximately 20% of the pilots in these 
cases were found to have been flying without a valid medical, and approximately 21% of the 
pilots were found to be medical professionals (Sen, Akin, Canfield, & Chaturvedi, 2007).  A final 
analysis indicated that in 19 of the 61 cases, the pilot’s SSRI use or psychological condition was 
the probable cause or contributing factor in the accident (see table 1 below) (Sen, Akin, Canfield, 






The SSRI-Involved Accidents Wherein the Psychological Conditions and/or the Use of SSRIs 
and/or Other Drugs Were Determined by the NTSB to be the Cause/Factor(s) 
 
Accident Probable Cause Contributing Factor(s) 
1 Suicide Other psychological condition 
2 – Use of a prescription drug 
3 Alcoholic and drug impairment of efficiency – 
 and judgment  
4 – Impairment due to use of drugs that 
were not 
  approved for use while flying 
5 Impairment of judgment and performance due – 
 to drugs  
6 Loss of control due to spatial disorientation Impairment due to medication 
7 – Use of contraindicated drugs 
8 – Use of unapproved medication 
9 Physiological impairment due to alcohol Psychological condition 
10 – Impairment of the pilot's judgment by 
the 
  use of a contraindicated drug, and his 
  overconfidence in his abilities 
11 – Use of prescription drugs not approved 
for 
  use by the FAA 
12 Alcohol impaired decision making – 
13 The pilot's incapacitation Inappropriate use of medication, and 
depression* 
14 – Impairment due to drugs/medication 
15 – Pilot's impairment (alcohol), and his 
  psychological condition 
16 – Drug impairment of the pilot as a result 
of 
  higher than normal levels of Benadryl 
17 – Use of FAA prohibited drugs 
18 – Impairment (drugs) of the private pilot 
19 – Use of inappropriate medications 
Note.  Reprinted from Sen, Akin, Canfield, & Chaturvedi, 2007, p. 5. 
Public Perception of Pilots 
Each of these aviation accident cases brings to question the mental stability of the pilots.  
However, in many cases, it may be difficult to discern what was going through the mind of these 
pilots before making a professional decision to fly an aircraft while mental fitness was in 
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question, or while consuming an unapproved medication.  Human factors, while having many 
definitions, can be viewed as the interaction between humans and their environments (Garland, 
Wise, & Hopkin, 1999).  While there appears to be speculation of underlying health issues in the 
Egypt Air and FedEx case, the Germanwings incident uncovered more tell-tale signs of 
underlying issues regarding mental health in pilots. 
According to the Flight Safety Foundation’s recommendation, pilots need an outlet to get 
the assistance they require without fear of reprisal from legislators, regulators, their employers, or 
the general public (FSF, 2016).  In September of 2015, a study was conducted that examined 
public stigma before and after the Germanwings crash.  Population surveys conducted in 
Germany between 1990 and 1991, and again after the Germanwings crash, indicated an increased 
stigma against people with a mental disorder than before the crash (Schomerus, Stolzenburg, & 
Angermeyer, 2015).  In one study, respondents indicated they would have been more willing to 
sublet a room to someone with known schizophrenic tendencies than after the Germanwings 
crash (Schomerus, Stolzenburg, & Angermeyer, 2015).  The results of the test indicated a change 
of respondent unwillingness by 24% (Schomerus, Stolzenburg, & Angermeyer, 2015). 
While social stigma can be an issue, there are those that feel the public should be made 
aware when a flight crew member is taking any medications.  A public comment posted on 
cbsnews.com stated: 
Passengers should be informed several days before a flight if either pilot or copilot are 
taking any medication that has even the remotest [SIC] possibility of presenting a danger 
to passengers so they can make an informed decision whether to take that flight or to 
change to a flight conducted by healthy non-medicated pilots (Jackson, 2010, p. 66). 
The public appears to demand that all airline pilots are mentally healthy and non-medicated 
individuals (Jackson, 2010).  However, it is not reasonable nor practical when the public has the 
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assumption that pilots are not human beings (Jackson, 2010).  This outlook does not make skies 
safer (Jackson, 2010). 
The FAA’s Airmen Medical Certification Process 
Before 2010, the FAA strictly prohibited pilots who were diagnosed with or suffered 
from, anxiety, depression, and/or taking an SSRI medication from receiving any class of medical 
certification (FAA, 2010a; Werfelman, 2008).  Additionally, those individuals were not allowed 
to act as pilot in command or exercise any privilege of their airman certificate (FAA, 2010a; 
Werfelman, 2008).  Applicants who had taken an SSRI in the past were required to demonstrate 
successful discontinuance of the medication for at least 90 days before consideration of a medical 
certificate was granted (FAA, 2010a; Werfelman, 2008).    
In 2010, the FAA began to change its certification procedures regarding pilots, anxiety, 
depression, and SSRI usage (FAA, 2010a).  Under certain circumstances, the FAA began making 
case-by-case evaluations of pilots who indicated they were diagnosed with anxiety or depression 
(FAA, 2010a).  Depending on the results of the evaluation, the FAA would allow some applicants 
to take one of four approved SSRI medications: (1) Lexapro; (2) Prozac; (3) Celexa; and (4) 
Zoloft (FAA, 2010a).  However, the FAA stipulated that an applicant must demonstrate 
successful use of the medication for a 12-month period (FAA, 2010a).  The FAA opened a 
temporary six-month window in which pilots could fully disclose any previous diagnosis of 
anxiety, depression, or SSRI use without taking any civil or criminal action against that pilot 
(FAA, 2010a).  
The FAA altered their view on the use of SSRI medications in part from changes in 
international policy from ICAO, the Civil Aviation Safety Authority (CASA) of Australia, 
Transport Canada, and other ICAO States (FAA, 2010a).  Increased pressure from the Aircraft 
Owners and Pilot Association (AOPA), the Airline Pilots Association (ALPA), and the Aerospace 
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Medical Association (AsMA) also prompted the FAA to reexamine its policies (FAA, 2010a; 
FAA, 2010b).  Furthermore, the U.S. Army began allowing some of its airmen to fly with limited 
privileges while using antidepressant medications (FAA, 2010a; FAA, 2010b).   
According to current FAA medical certification standards, U.S. pilots are required to 
indicate on their medical application if they are taking an SSRI and if one has ever been 
diagnosed with anxiety or depression (FAA, 2017b).  The aviation medical examiner (AME) is 
instructed not to issue a medical certificate and submit the application for further evaluation by 
the FAA (FAA, 2017b).  Once a medical application has been submitted, the pilot must be 
monitored and re-evaluated after six months of a consistent single-dose usage of one of the four 
FAA approved medications (FAA, 2017b).  Initial evaluations and monitoring are conducted by 
an appropriate mental health specialist (e.g., a psychiatrist) (FAA, 2017b).  After completion of 
the six-month demonstration period, a pilot can request a re-evaluation of their mental health 
condition from their treating psychiatric care physician (FAA, 2017b).  A physician’s statement 
must verify that no adverse effects have been noted and the mood disorder is under control by an 
approved FAA treatment method (FAA, 2017b).  Lastly, an authorized medical specialist with the 
FAA aeromedical division will evaluate all documentation and grant, or deny, the request for a 
medical waiver (FAA, 2017b).  A pilot may apply for a medical certificate without a waiver or 
restrictions after a 60-day period of discontinuance of any SSRI medication and a favorable report 
from the treating physician stating that there are no undesirable side effects (FAA, 2017b).  In 
addition, the report must indicate that the applicant’s mood is stable (FAA, 2017b).   
The FAA cautions aviation medical examiners (AMEs) that when certifying airmen, 
multiple considerations must be made (Gordon, n.d.).  Even if a medication is on an approved 
FAA list, it should be determined why the medication was being prescribed to the pilot (Gordon, 
n.d.).  Therefore, the condition, rather than the medication, may be the disqualifying factor 
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(Gordon, n.d.).  The FAA offers AME guidance regarding certification via a pathway decision-
making system (see figure 11 in Appendix G) (FAA, 2018).  
According to FAA AME medical certification guidance (2018), Pathway I assumes an 
applicant is currently prescribed and taking an SSRI medication.  After consulting an AME, the 
applicant will determine whether to continue or discontinue use of the medication.  For a 
discontinuance of an SSRI medication, the applicant is informed there will be a 60-day waiting 
and demonstration period.  If the applicant chooses to continue using an SSRI, then the AME 
must confirm that the applicant is currently consuming only a single-dose of an FAA-approved 
SSRI medication.  If the medication is not on the approved list, then an applicant will be denied 
and advised their action is not acceptable.  If the applicant agrees to continue with an approved 
SSRI medication, then AMEs are referred to Pathway II (FAA, 2018). 
According to FAA medical certification guidance (2018), should an AME proceed to 
Pathway II, then the examiner will determine whether the applicant has been on an approved 
medication for a six-month period or less.  If less than six months, then an applicant will be 
advised to continue the medication until the six-month period has ended or defer an applicant to 
Pathway I where they may elect to discontinue usage.  Should the applicant demonstrate 
successful usage of the medication for six months or more, then the AME is instructed to evaluate 
the underlying reasons for prescribing the medication to the pilot.  The AME must verify that the 
SSRI medication has not been combined with any other psychiatric medications, and the 
applicant has not been diagnosed with any other unacceptable mental conditions (FAA, 2018). 
According to FAA guidance (2018) if the AME determines that conditions are favorable 
for the pilot to move forward in the process, then the airmen will be instructed to complete an 
Airman Information – SSRI Initial Certification sheet (see figure 12 in Appendix G).  This 
information sheet requires the airman to fully disclose detailed information regarding one’s 
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medical history of anxiety or depression, prescribed medications, and attest to their understanding 
of the certification process.  Airmen are instructed that during this period one must discontinue 
flying while their case is being evaluated by the FAA (FAA, 2018).  
BasicMed 
In January 2017, the FAA published its final ruling regarding BasicMed certification.  
The new rule created an alternate medical certification option for pilots seeking a third-class 
medical.  However, there are certain limitations regarding the types of flight operations a pilot is 
authorized to conduct when certified under the BasicMed program.  A pilot issued a medical 
certificate under BasicMed is limited to: (1) aircraft operations carrying no more than five 
passengers; (2) an aircraft with no more than six seats; (3) flights may be conducted under visual 
flight rules (VFR) or instrument flight rules (IFR); (4) airspeed restrictions below 250 knots; (5) 
flight operations below 18,000 feet; and (6) all flight operations must be restricted to the 
continental U.S.  Additional prerequisites must be met before the pilot can qualify for BasicMed.  
These prerequisites include: (1) a valid driver’s license; (2) a valid FAA medical issued after July 
2016; (3) the most recent medical application was not denied; and (4) the most recent medical 
certificate has not been revoked or suspended (FAA, 2017c). 
According to FAA guidance (2017), applicants receive a physical exam from any state-
licensed physician.  The physician will reference a comprehensive medical examination checklist 
regarding items that require evaluation.  The physician will evaluate all items on the checklist and 
decide that no conditions exist, nor are any medications being taken, that would interfere with an 
applicant’s ability to operate an aircraft.  Once the examination is complete, the applicant is 
required to complete an online training course. These courses must be completed every two years, 
and examinations are valid for 48 calendar months (FAA, 2017c; FAA, n.d.a). 
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In July 2016, Congress passed the Federal Aviation Administration Extension, Safety, 
and Security Act (FESSA) (FAA, 2017a).  The purpose of the legislation was to provide medical 
relief for pilots operating small aircraft; however, the legislation is limiting in the definition of a 
mental disorder (FAA, 2017a).  Currently the FAA allows pilots who suffer from mood disorders 
and/or taking an SSRI to operate as pilot in command with certain resections (FAA, 2017a).  
While only applying to BasicMed applicants, FESSA defines those suffering from mental 
disorders as having been diagnosed with personality disorder, bipolar disorder, substance 
dependence, or psychosis (FAA, 2017a).  Therefore, the act appears to exclude those suffering 
from anxiety or depression from requiring a special medical issuance under BasicMed (FAA, 
2017a).  However, those applying for medical certificate privileges higher than a third-class are 
still required to follow the FAA guidance for special issuance regarding those taking an SSRI, 
and not eligible for BasicMed (FAA, 2017a; FAA, 2017b). 
ICAO, ICAO States, and the Medical Certification Process 
The International Civil Aviation Organization (ICAO) 
The International Civil Aviation Organization (ICAO) began promoting mental health 
advocacy before the FAA agreed to make considerations for U.S. pilots suffering from anxiety, 
depression, and/or those taking an SSRI.  The concept stemmed from the understanding that 
isolating those with certain mental health disorders led to social stigmas and was in violation of 
human rights (Presenter, Jordaan, 2016).  Therefore, a more positive approach was needed 
regarding mental health issues in aviation (Presenter, Jordaan, 2016).  According to Dr. Ansa 
Jordaan, Chief of Aviation Medicine for ICAO (2016), the organization acknowledges the full 
magnitude of mental health issues in global aviation is unknown.  Many factors contribute to 
these challenges.  Pilots may not disclose certain conditions due to several reasons which can 
include job termination, social stigmas, lack of trust from medical professionals, cost of 
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examinations and medications, loss of flight status, or possible discrimination.  Moreover, a lack 
of understanding what medical and/or professional resources are available to an individual may 
also lead to a reluctance of full disclosure (Presenter, Jordaan, 2016). 
ICAO guidance (2008) suggests pilots should be regularly monitored especially during 
the first two years of any mental health recovery period.  During recovery, even though relapses 
are rare, symptoms can resurface.  However, based on research from ICAO States and the 
Aerospace Medical Association (AsMA), ICAO reports that SSRIs can effectively be used in the 
treatment of certain conditions.  Moreover, newer SSRIs often have a lower rate of side effects 
making them ideal for airmen.  Nonetheless, ICAO recommends that before an SSRI is 
prescribed, a full diagnosis of conditions must be established and monitored (ICAO, 2008). 
According to ICAO (2008), each licensing State has the authority to set its own limits 
when determining if, or how, to certify an airman that has been diagnosed with anxiety, 
depression, and/or taking an SSRI.  However, ICAO makes several recommendations regarding 
what each State should consider during the certification process.  These recommendations 
include: (1) the airman should be under the care of a trained and experienced mental health 
practitioner; (2) the airman should be in a stable condition and have no adverse side effects to the 
prescribed treatment; (3) the airman should receive regular clinical reviews and not be diagnosed 
with additional psychiatric disorders; and (4) the airman should have no history of psychosis, 
suicidal tendencies, or sleep disorders (ICAO, 2008).  However, ICAO does not offer guidance 
regarding what types of SSRI medications are acceptable and implies those decisions are left to 
each ICAO State (A. Jordaan, personal communication, July 12, 2018). 
The Civil Aviation Safety Authority (CASA) of Australia  
The Civil Safety Aviation Authority (CASA) of Australia has conducted more research 
regarding SSRI use in airmen than other ICAO States.  As early as 1987, CASA has allowed 
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many pilots and air traffic controllers to take an SSRI and obtain a medical certificate (Ross, 
Griffiths, Dear, Emonson, & Lambeth, 2007).  Moreover, CASA certified these airmen while 
other ICAO States insisted SSRI medications were not compatible with aviation safety (Ross, 
Griffiths, Dear, Emonson, & Lambeth, 2007).  Furthermore, CASA regulations allow its pilots to 
take either an SSRI or an SNRI (Ross, Griffiths, Dear, Emonson, & Lambeth, 2007). 
Regarding airmen certification, CASA follows suggested certification protocol set forth 
by ICAO (Ross, Griffiths, Dear, Emonson, & Lambeth, 2007).  Airmen must demonstrate 
successful treatment of a given medication for at least four weeks before regaining flight status 
(Ross, Griffiths, Dear, Emonson, & Lambeth, 2007).  An airman may be required to submit a 
progress report at least once every six months (Ross, Griffiths, Dear, Emonson, & Lambeth, 
2007).  Lastly, clinical reviews of the airman may be expected within the first year of certification 
which may extend beyond the first year (Ross, Griffiths, Dear, Emonson, & Lambeth, 2007). 
Even though CASA may be more liberal with its regulations by allowing airmen to take 
antidepressant medication, CASA research concludes there were few documented cases of 
accidents in which pilots had an antidepressant in their system (Ross, Griffiths, Dear, Emonson, 
& Lambeth, 2007).  In addition, there had been no significant studies to link aviation safety to 
SSRI usage (Ross, Griffiths, Dear, Emonson, & Lambeth, 2007).  In a ten-year study, CASA 
evaluated 481 pilots taking an SSRI and found there to be no direct link or quantifiable 
measurement to a decrease in safety (Ross, Griffiths, Dear, Emonson, & Lambeth, 2007). In 
addition, CASA has concluded that pilots taking an SSRI pose no significant safety threat when 
compared to individuals who do not suffer from the disorder (Nowak, 2007).  The conclusions 
came after evaluating eleven accidents and 22 near misses (Nowak, 2007).  
Researchers concluded that while pilots in these cases had SSRIs in their system, these 
cases were similar in number to those cases in which pilots were not taking an SSRI (Nowak, 
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2007).  Some studies have indicated that overall safety records have improved in Australia.  
Between 1993 and 2002, the Australian Transport Safety Bureau (ATSB) indicated an increase in 
flying by 18% with a decline in accident rates (Ross, Crisp, Lambeth, Griffiths, & Dear, 2005).  
Moreover, new generation SSRIs have increasingly become more effective with fewer side 
effects than earlier antidepressants (Ross, Crisp, Lambeth, Griffiths, & Dear, 2005).  
The Civil Aviation Authority (CAA) of New Zealand 
The Civil Aviation Authority (CAA) of New Zealand has also begun allowing some 
pilots the ability to obtain medical certification while taking certain SSRIs.  Each applicant is 
evaluated on a case-by-case basis, and the CAA evaluates many factors before considering an 
applicant (CAA New Zealand, 2013).  These include: (1) circumstances surrounding the anxiety 
or depression; (2) how long ago the symptoms occurred; (3) the degree of seriousness; (4) the 
nature and effectiveness of the treatment; (5) the amount of time since remission of symptoms; 
and (6) the current health status of the applicant (CAA New Zealand, 2013).  The CAA cautions 
that while some applicants may be taking medication or seeking other treatment options, not all 
medical applications will be accepted (CAA New Zealand, 2013).  The CAA states that even if an 
applicant is granted a medical certificate in New Zealand, this does not guarantee that other 
countries will do the same (CAA New Zealand, 2013).   
Transport Canada 
Transport Canada (2018b) currently certifies flight crews who have been diagnosed with 
anxiety or depression to maintain flight status and obtain a medical.  Transport Canada began to 
change its stance on the topic after research concluded that approximately 6% of the general 
population suffers from some form of mood disorder.  This same ratio is also found to exist 
among flight crews.  As with other ICAO States, each Canadian applicant is evaluated on a case-
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by-case basis.  Applicants must demonstrate no adverse side effects exist with any prescribed 
medication or treatment option (Transport Canada, 2018b).   
Transport Canada began studying the effectiveness of SSRIs and pilots in the mid-1990s 
(Werfelman, 2008).  In 2001, Transport Canada conducted additional studies on the subject which 
included a review of international assessments (Werfelman, 2008).  Transport Canada concluded 
that individuals who have been successfully treated while under appropriate psychiatric care may 
have their medical application forwarded to the Civil Aviation Medicine Division (CAM) board 
for review.  If approved, crew members are allowed to operate in a multi-crew setting 
(Werfelman, 2008).   
Additional Transport Canada research (2018b) has indicated there were circumstances 
where flight safety was not compromised by those who were taking an SSRI or SNRI for 
treatment.  In addition, effective treatment options were found to preserve the relationship of 
well-trained flight crews.  However, there were indications that some medical professionals were 
found colluding with patients in order to prescribe unapproved medications, or other treatment 
options, to avoid potential grounding of the pilot.  For example, some medical practitioners were 
found to have prescribed an antidepressant to individuals by falsifying the diagnosis and reason 
for the prescription.  In some cases, prescribers indicated the purpose for a given medication was 
to act as a stop smoking aid rather than treatment for a mood disorder (Transport Canada, 2018b). 
Transport Canada (2018b) allows prescribing of certain SSRIs for the treatment of 
multiple disorders including anxiety and/or depression, acute stress, adjustment disorders, and 
post-traumatic stress disorders.  Moreover, SSRIs are acceptable treatment methods for eating 
disorders, obsessive-compulsive disorders, and social phobias.  Applicants being treated for one 
or more of these disorders must submit a detailed report from their treating physician along with 
the application for certification.  The physician must outline the diagnosis along with the 
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applicant’s medication history and its effectiveness.  Additionally, physicians must testify to the 
treatment’s effectiveness and the user’s lack of suicidal tendencies.  If an applicant is taking a 
medication, then the report must indicate that an applicant has been taking the medication for a 
period no less than four months.  Lastly, there must be an absence of side effects (Transport 
Canada, 2018b). 
All Transport Canada applicants (2018b) must participate in follow-up evaluations once 
they have been granted a medical certificate.  Part of the evaluation process includes undergoing a 
psychiatric examination every six months for the duration of the treatment.  Should an applicant 
choose to discontinue medication or treatments, then that applicant must obtain a statement from 
the treating physician testifying that an applicant is in a stable condition with no adverse side 
effects, lapses, or suicidal tendencies.  A psychiatric follow-up is required six months after 
cessation of medication and treatment.  In either case, a flight simulator check may be required to 
support any assessments by the medical profession (Transport Canada, 2018b). 
The Civil Aviation Authority (CAA) of the UK 
The Civil Aviation Authority (CAA) of the United Kingdom (UK) began certifying pilots 
suffering from depressive disorders in 2012 (Presenter, Hutchinson, 2013).  Pilots are considered 
unfit for a minimum of four weeks until symptoms are resolved (Presenter, Hitchinson, 2013).  
Once four-weeks have elapsed, an airman’s application will be reviewed by a CAA specialist in 
psychiatry (Presenter, Hutchinson, 2013).  All UK applicants are evaluated using a Hamilton 
Depression Scale (Presenter, Hutchinson, 2013).  The Hamilton Depression Scale (see figure 13 
in Appendix G), or HDRS, is a questionnaire commonly used by professional clinicians 
worldwide (Hamilton. 1960).  Some versions of the scale include either 17 or 21 questions which 
the professional clinicians use to evaluate a patient (Hamilton, 1960).  Each question is graded on 
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a numerical scale ranging from 0 thru 4 while rating symptoms from least moderate to most 
severe respectively (Hamilton, 1960). 
All UK applicants applying for a medical waiver are required to take a flight or simulator 
check, and once approved, the applicant is labeled restricted to flying, “As or with a qualified co-
pilot” (Presenter, Hutchinson, 2013).  Applicants are also required to complete regular follow-up 
visits with a CAA psychiatrist (Presenter, Hutchinson, 2013).  At any time should a pilot elect to 
discontinue an SSRI, the pilot must complete a minimum of a two-week period of discontinuance 
before flight status will be reinstated to the pilot (Presenter, Hutchinson, 2013).   
Current U.S. Research Regarding Pilot Compliance 
Studies have been conducted evaluating the topic of mood disorders and SSRI 
medications in pilots.  However, the topic is still an apparent source of contention.  Public views 
of pilot mental health may become a deciding factor regarding how aviation authorities choose to 
certify their pilots.  Studies conducted in the U.S. between 1993-2012 concluded that pilot suicide 
rates were approximately 0.33% (Persaud, & Bruggen, 2015).  Similar studies in the UK between 
1956-1995 had almost identical results indicating rates at 0.3% (Persaud, & Bruggen, 2015).  In 
addition, a German study concluded that between 1974 and 2007 the suicide rate among pilots 
was only 0.29% (Persaud, & Bruggen, 2015). Yet many pilots are afraid to come forward even 
though symptoms of anxiety and depression are typically short-term with minimal chances of 
reoccurrence after treatment (Persaud, & Bruggen, 2015).  The FAA stated that inquiries to the 
Aviation Medicine Advisory services indicated that approximately 59% of airmen do, or would, 
refuse to use SSRI medication if they were prescribed one (Persaud, & Bruggen, 2015).  
Moreover, approximately 15% of airmen indicated they would take SSRI medication without 
notifying the FAA (Persaud, & Bruggen, 2015). 
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Between 1997-2001 the Airline Pilots Association (ALPA) stated that over 1,200 pilots 
contacted their offices indicating a recent diagnosis of depression (Presenter, Evans, 2013).  
Approximately 60% of those who contacted the ALPA indicated they would continue flying 
without taking necessary medications (Presenter, Evans, 2013).  Approximately 15% advised they 
would take the recommended medications without adequately notifying the FAA (Presenter, 
Evans, 2013).  Approximately 25% indicated they would take the recommended medications and 
cease flying (Presenter, Evans, 2013). 
In 2007, statements given during a Congressional hearing identified the possibility of 
airmen falsifying medical records to maintain their flight status.  The FAA notes when a pilot is 
neither mentally nor physically fit to fly, they not only pose dangers to themselves, but to 
everyone else they have contact with while operating an aircraft.  In 2005, the Inspector General 
(IG) for the Department of Transportation (DOT) found multiple cases in which airmen were 
found to have lied or omitted potentially debilitating information on medical applications.  The 
IG sampled 40,000 airmen with valid medical certificates and discovered that 3,200 of those 
airmen were also receiving disability payments from the U.S. government.  In addition to these 
findings, the IG noted cases in which the FAA investigated fatal accidents where the pilot was 
found to have withheld potentially disqualifying medical information (Federal Aviation 
Administration’s Oversight of Falsified Airman Medical Certificate Applications, 2007). 
Despite these findings and testimonies (2007), the FAA maintained that the falsification 
of medical information was negligible when compared to the total U.S. pilot population.  In 2006, 
the FAA released a report based on findings from 4,143 fatal accidents between 1993 and 2003.  
The report indicated that of all the accidents studied, approximately 10% of the pilots were found 
to have past issues concerning mental, neurological, or cardiovascular disorders.  However, these 
deficiencies were not noted on the airman’s medical application.  The IG recommended the FAA 
institute a program to periodically cross-check and verify applicant medical history along with 
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disability claims (Federal Aviation Administration’s Oversight of Falsified Airman Medical 
Certificate Applications, 2007). 
Alternative Treatment Options 
While mood disorders are undesirable, pilots do have effective treatments options other 
than medication.  Counseling or speaking with someone regarding anxiety or depressive issues 
can be beneficial (Stoutt, n.d.).  Pilots are encouraged to avoid alcohol as in most cases alcohol is 
a form of self-medicating which can worsen symptoms of anxiety or depression (Stoutt, n.d.). 
Individuals who continue to drink alcohol while prescribed SSRI medication may experience 
undesirable effects including an increase in depression, fatigue, or insomnia (Nicholson, 2003).  
In addition, some over-the-counter herbal and nutritional supplements have been known to have 
unwanted side effects as well (Nicholson, 2003).  These supplements include St. John’s Wart, 
pink grapefruit juice, and ginkgo biloba (Nicholson, 2003).  All of these could create additional 
stress, cause changes in mental status, restlessness, and in some cases an increase in internal 
bleeding (Nicholson, 2003).   
Regular exercise releases endorphins that help the body combat stress and fatigue which 
can help alleviate frustration, hostility, and anger (Stoutt, n.d.).  Lastly, personal acceptance and 
forgiveness is also an accepted method of treatment regarding anxiety and depression issues 
(Stoutt, n.d.).  A crucial step in the recovery process occurs when a pilot understands they are not 
battling a mood disorder by themselves, nor is their condition is unique (Stoutt, n.d.). 
Regardless of treatment options, pilots need to have access to an array of support 
systems.  Unfortunately, professional aviators are hesitant and distrusting of mental health 
professionals (Bor, Field, & Scragg, 2002).  Often it is the social stigma that deters a pilot to seek 
professional help with mental health issues (Bor, Field, & Scragg, 2002).  Publicly, pilots have 
always been portrayed as having a glamorous lifestyle; carrying large amounts of responsibilities 
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with a sense of calm and coolness (Bor, Field, & Scragg, 2002).  This perception can affect how 
or when a pilot chooses to seek help. 
Research Promoting Regulatory Change in Treatment Options for Pilots 
Multiple organizations are conducting ongoing research and have made 
recommendations in support of allowing for more flexibility regarding treatment options for 
pilots suffering from anxiety or depression (FAA, 2010b).  Additionally, recommendations have 
been made that allow for increased flexibility in the number of SSRI medications available to 
pilots (FAA, 2010b).  There are more than 40 medications commonly prescribed in the U.S. as an 
antidepressant of which the top five of those medications are SSRIs (FAA, 2010b).  Many ICAO 
States have already adopted more flexible policies than the FAA for the use of additional 
medications (FAA, 2010b).  Some of the important studies and recommendations include: 
1. The Aerospace Medical Association (AsMA) has published and made 
recommendations that the FAA allow usage of SSRIs.  
2. Aircraft Owners and Pilots Association (AOPA) has recommended a proposed rule 
change allowing for certain SSRI usage in U.S. pilots. 
3. The Airline Pilots Association (ALPA) has issued a statement proposing a policy for 
granting special issuance medical for those taking an SSRI with ongoing medical 
monitoring.  
4. The Civil Aviation Safety Authority (CASA) of Australia began allowing pilots in 
1987 to use certain SSRI medications.  A ten-year follow up from 1993-2004 of 481 
pilots indicated no increase in accidents.  
5. ICAO has adopted a Recommended Practice that allows ICAO States to certify 
applicants on a case-by-case basis for those taking an approved SSRI by the 
governing State authority. 
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6. Transport Canada has allowed a limited number of pilots to use one of three 
approved medications while operating in a multi-crew setting. 
7. The U.S. Army has offered waivers for select pilots to use SSRIs (FAA, 2010b). 
The Aerospace Medical Association (AsMA) encourages each ICAO State to conduct 
their own research on the topic (Jones & Ireland, 2004).  AsMA also encourages the use of 
outside contractors if necessary, to assist in the process (Jones & Ireland, 2004).  Nonetheless, 
there should be a unified study on the subject within the international community rather than 
unilateral decisions from each State.  Decisions should be made with the absence of legal or 
political pressures (Jones & Ireland, 2004).  While more recent studies and data are limited within 
the aviation communities, previous data is readily available regarding automobile, truck, and bus 
operations which shows little to no adverse side effects regarding the safety of those operations 
(ATSB, 2006; Jones & Ireland, 2004).   
Evidence indicates pilots requiring medication have refused to do so due to fear of being 
grounded (Jones & Ireland, 2004).  Considerable evidence exists demonstrating that pilots are 
choosing to take medication for anxiety or depression without disclosing one’s condition (Jones 
& Ireland, 2004).  Australian and Canadian agencies have demonstrated that pilots when properly 
monitored can safely operate aircraft while being medicated (Jones & Ireland, 2004).  States 
should evaluate pilots based on ICAO recommendations (Jones & Ireland, 2004).  Further 
recommendations include greater attention to pilot mental health issues (Presenter, Evans, 2013).  
This should be accomplished not only by medical examiners, but throughout the aviation 
community as well (Presenter, Evans, 2013).  
Airmen need to have a wealth of resources made available to them to be successful in 
recognizing, treating, and coping with anxiety or depression (Presenter, Scarpa, 2014).  Family 
members, as well as the aviation community, need to become more educated on the topic 
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(Presenter, Scarpa, 2014).  There should be more awareness regarding mental health issues in 
aviation.  While seeking professional help is essential, there should be resources beyond a general 
care physician (Presenter, Scarpa, 2014).  Pilots should receive regular training to help identify 
underlying conditions while learning to manage mental health issues (Presenter, Scarpa, 2014).  
Crew resource management (CRM) training should incorporate recognition and management 
techniques (Presenter, Scarpa, 2014).  A global training standardization should be incorporated 
(Presenter, Scarpa, 2014). 
Dr. Anthony Evans, former Chief of Aviation Medicine Section at ICAO, and Dr. Sally 
Evans of the UK’s Civil Aviation Authority (CAA), concluded that creating policies aimed at 
effective treatment and monitoring those taking antidepressants is far better than those which 
penalize and ground pilots for seeking or requiring treatment (Werfelman, 2008).  Both ICAO 
and the UK have concluded that existing policies are far more likely to result in pilots flying 
untreated or flying while failing to disclose medical issues (Werfelman, 2008).  Such policies 











This chapter describes the methodology used in this research study, to include: the 
purpose of the study, selection of the population, data collection, data analysis, and ethical issues 
and assurances.   
Purpose of the Study 
The purpose of this research study was two-fold.  The findings from the study should 
help conclude whether the FAA’s viewpoints regarding mood disorders and treatment options are 
too stringent or outdated when compared to recommendations by ICAO and the medical 
certification standards of other ICAO States.  In addition, the responses from the participating 
U.S. pilot group should help identify how familiar they are with FAA views regarding mood 
disorders and SSRI use in airmen, as well as indicate whether current FAA medical certification 
standards for mood disorders and SSRI use are beneficial to the U.S. pilot population. 
Selection of the Population 
Three distinct population groups were invited to participate in this research study.  Group 
I comprised of representatives from aviation governing agencies and their respective medical 
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certification divisions.  Group II comprised of U.S. certificated pilots.  Group III comprised of a 
non-aviation medical professional 
Group I agencies invited to participate in this study were: 
1. The Civil Aviation Authority of the UK (CAA); 
2. The Civil Aviation Safety Authority (CASA) (Australia); 
3. The Directorate General for Civil Aviation (DGAC) (France); 
4. The Federal Aviation Administration (FAA) (United States); 
5. The International Civil Aviation Organization (ICAO) (headquartered in Montreal); 
6. The Luftfahrt-Bundesamt (LBA) (Germany); 
7. The Swedish Transport Agency (STA); and 
8. Transport Canada (TC). 
Group I participants were selected by the researcher based on current research 
contributions related to the subject of anxiety, depression, and SSRI use in the pilot population. 
Transport Canada and CASA are pioneer ICAO States regarding research, acceptance, and 
certification procedures for airmen suffering from anxiety, depression, and/or taking an SSRI. 
ICAO was asked to participate because the organization issues guidance on the subject for other 
ICAO States to consider when certifying their airmen (ICAO, 2008).  The FAA was selected for 
comparative purposes with ICAO and other ICAO States.  Each ICAO State received an email 
requesting a preview of the intended interview or survey questions and who in the agency would 
be able to answer each question before beginning interviews and surveys.        
Group II was a sampling of the U.S. pilot population.  The researcher did not specify any 
participation requirements regarding levels or type of certificates held, nor experience.  
Participation was available to any U.S. certificated pilot age 18 or older.  Group III comprised of 
a non-aviation medical professional.  A non-aviation medical professional was invited to 
participate in the study and provide a non-aviation medical interpretation of the FAA’s responses 
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to the survey questions. The purpose of this opinion was to develop a comparison between two 
distinct medical standards: general medicine vs. aerospace medicine.  Moreover, guidance from 
the non-aviation medical professional was sought to determine if any safety concerns are 
prevalent in those individuals prescribed an SSRI while operating an aircraft.   
Data Collection 
Group I 
Participants in Group I received an email asking whether a representative of each agency 
would be able to preview intended research questions.  Emails were sent to eight aviation 
governing agencies requesting a preview of intended interview or survey questions.  Once an 
agency responded, the agency-approved questions were then forward to the appropriate 
department or individuals.  Each agency was contacted outlining the scope and purpose of the 
study.  A request was made to each agency for an authorized medical professional with 
knowledge of administrative policies and to participate in a brief telephone or Skype interview.  
The researcher developed a list ten interview/survey questions and included these questions in the 
email invitation.  ICAO received a request from the researcher to answer nine interview questions 
(see Appendix B; see Appendix C). 
Due to time constraints, most of the aviation governing agencies willing to participate in 
this research study decided to provide written answers through email communication instead of 
providing verbal responses.  Four agencies responded to the preview questions that were to be 
reviewed rather than indicating if the agency was willing and able to participate.  These agencies 
include the FAA, Transport Canada, the Civil Aviation Authority of the UK, and the Swedish 
Transport Agency.  The interview questions focused on the agency’s knowledge and opinion 
regarding the following topics: 
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1. The FAA’s past and current certification process of airmen diagnosed with or 
suffering from, anxiety, depression, and/or taking an SSRI. 
2. Why did a given agency, if applicable, choose to change its opinion and the 
certification process for airmen diagnosed with, or suffering from, anxiety, 
depression, and/or taking an SSRI? 
3. What information does a given agency consider when making policy changes? 
4. Are there other options available to airmen should a specific medication or treatment 
option not be a viable solution for a given individual? 
5. Are there other factors for a given agency that may result in denial of a medical 
application even though that airmen met and complied with the application process? 
6. Does a given agency have policies in place to ensure airmen compliance with new 
standards? 
7. Does a given agency estimate how many airmen are, or are not, complying with the 
certification standards? 
8. Evaluate a statement from the Australian Civil Aviation Safety Authority regarding 
individuals that take medication for anxiety and/or depressive disorders are no more 
dangerous than those who have not been diagnosed with, nor suffer from, one of 
these disorders. 
9. Determine if the FAA’s certification standards are more or less restrictive than 
ICAO’s recommendations. 
10. Any additional comments. 
Responses from each of the governing agencies were collected and stored on a 
password-protected computer for evaluation and comparison.  The researcher did not request 
personal information; therefore, no encryption of collected information was necessary.  Each of 
the participating agencies received a Waiver of Documentation advising each agency that 
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collected data would be used for a doctoral dissertation and may be replicated and published with 
the consent of the researcher (see Appendix B). 
Group II 
Based on 2017 FAA statistics, there were 609,306 valid pilot certificates issued in the 
U.S. (FAA, 2017d).  Using this reported population size for the Group II population, a confidence 
level of 95% that yields a Z-Score of 1.96, and an estimated margin of error with a value of 4, the 
researcher determined that a sample size of 600 Group II participants would be required for this 
study.  The Group II population was invited to participate through email communications, 
professional pilot forums, and word-of-mouth.  Each certificated pilot represented in Group II 
was asked to complete an anonymous four-question survey questionnaire (see Appendix B; see 
Appendix D).  The closed-end survey questions only required a yes or no response. Group II 
participants were asked to respond to the following topics: 
1. Whether the participant agreed to the adequacy of the FAA’s policy regarding pilot 
medical certification standards for anxiety and depression before 2010; 
2. Whether the participant agreed to the adequacy of the FAA’s policy regarding pilot 
medical certification standards for anxiety and depression after 2010; 
3. Whether the participant agreed to the adequacy of the FAA’s policy regarding pilot 
medical certification standards for anxiety and depression in 2015; and 
4. Whether participants agreed to and were aware of Australia’s research, views, and 
pilot medical certification standards for anxiety and depression dating back to the 
1980s.      
Email invitations to participate in the study were sent to administrators with the following 
institutions and asked to forward invitations to their respective student body: Oklahoma Aviation, 
Oklahoma State University, University of Oklahoma, Southeastern Oklahoma State University, 
43 
 
and Embry Riddle Aeronautical University (Daytona Beach campus).  The National Business 
Aviation Association’s (NBAA) database was used by the researcher to identify corporate flight 
operators in each state.  Lists for each state were randomized to maintain objectivity, and the first 
two flight departments generated from each state were sent email invitations inviting their 
employed certificated pilots to participate in the survey.  Email addresses and company 
information was kept confidential.   
Lastly, invitations to participate in the survey were posted on the following three 
professional pilot forums  
1. Airlinepilotcental.com; 
2. Jetcareers.com; and 
3. Propilotworld.com. 
Approximately 1,570 invitations were issued to participate in the survey.  Five invitations 
were sent to the flight schools.  One hundred email invitations were sent to a random selection of 
corporate flight departments in the U.S.  Approximately 320 individuals viewed the survey 
invitation from propilotworld.com, approximately 520 from airlinepilotcentral.com, and 
approximately 630 from jetcareers.com.  A total of 148 respondents participated in the survey 
over 45 days.  Survey responses from Group II were collected and stored on a password-protected 
computer for evaluation and comparison (see Appendix B; see Appendix D; see figure 14 in 
Appendix G). 
Group III 
An email invitation was sent to the Group III participant; a non-aviation medical 
professional.  The medical doctor was asked to evaluate the collected data from the FAA 
responses to in this research study and provide a professional opinion regarding FAA current and 
44 
 
past industry standards regarding airmen certification for those suffering from anxiety, 
depression, and/or an SSRI.  The survey questions for Group III focused on the following topics: 
1. Professional opinion regarding FAA policies regarding anxiety, depression, and 
SSRIs. 
2. Professional opinion regarding FAA decision to only allow four SSRI medications to 
be prescribed to airmen. 
3. Professional opinion regarding the benefits of the four approved medications vs. 
other treatment options or medications. 
4. Professional opinion regarding whether FAA policy regarding pilot medical 
certification standards for anxiety and depression was adequate before 2010. 
5. Professional opinion regarding whether FAA policy regarding pilot medical 
certification standards for anxiety and depression was adequate in 2010. 
6. Professional opinion regarding whether FAA policy regarding pilot medical 
certification standards for anxiety and depression was adequate in 2015. 
7. Professional opinion when comparing ICAO and ICAO State certification standards 
to the FAA. 
A non-aviation medical professional agreed to participate in the study but chose to 
respond to the interview questions in writing.  In addition, the doctor volunteered to forward the 
interview questions to other practitioners within Group III to obtain additional comments 
regarding the questions.  Responses from Group III was collected and stored on a password-
protected computer for evaluation and comparison (see Appendix B; see Appendix E). 
Invitations sent to Groups I and III received a Waiver of Documentation.  Invitations sent 
to Group II included a link which required activation to access and complete the survey.  The 
online survey software, SurveyMonkey, was used as the data collection tool.  All of the data 
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collected by the participants was securely stored compliance with SurveyMonkey protocol.  None 
of the survey questions asked for email registration, participant names, or disclosure of medical 
information.  Moreover, participation in the research survey participation was anonymous and 
voluntary.  All participants were required to review and agree to an electronic consent form 
before completing the survey (see Appendix B; see figure 15 in Appendix G). 
Data Analysis 
Group I 
Data analysis of Group I was evaluated based on interview or survey questionnaire 
results and a given State’s certification standards.  Group I was comprised of an FAA 
representative, an ICAO representative, and selective ICAO State aviation authorities.  Responses 
were evaluated and compared using descriptive statistical analysis.  Comparisons were made 
between each agency that participated against similar questions from the other agencies.  In 
addition, a comparison to current certification standards from ICAO and other ICAO States was 
used.  
Group II  
Group II responses were evaluated using descriptive statistical analysis.  In addition, 
graphs were used to represent respondent answers in comparison to others who participated.  
Group II responses were anonymous with no identifying information.  A descriptive statistical 
analysis was used to compare Group II responses to FAA certification standards.  
Group III  
Group III responses were evaluated using descriptive statistical analysis.  Non-aviation 
medical responses were used as a comparison to medical standards and practices outside of 
aviation.  In addition, Group III participants were asked to evaluate the FAA’s survey 
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questionnaire responses and provide additional information to help compare the difference in 
medical practices. 
Ethical Issues and Assurances 
This research study was conducted in accordance with Institutional Review Board (IRB) 
requirements established by the Oklahoma State University Office of University Research 
Compliance (URC).  The researcher applied for review of human subject research to the URC 
Office in April 2018.  The researcher obtained IRB approval (IRB Application Number: ED-18-
38, April 2018) from the URC before conducting any research and collecting data from 
participants.  University IRB protocol has been carefully followed by the researcher ensuring that 
all data collected from the participants has been protected through all IRB requirements, and all 







The focus of this research study was to evaluate the Federal Aviation Administration’s 
(FAA) medical certification process for certificated pilots suffering from or diagnosed with 
anxiety, depression, and/or taking an SSRI and comparing those standards to the International 
Civil Aviation Organization (ICAO) guidance and other ICAO State certification standards.  
Since 2015, the FAA has relaxed its certification standards for those applying for an airmen 
medical certificate (FAA, 2017b).  However, those standards may still be more stringent, limited, 
or outdated when compared to other ICAO States. 
The review of the literature has indicated that anxiety and depressive disorders are among 
the most common of all mental disorders diagnosed in the U.S. (Stoutt, n.d.).  Approximately 
80% of individuals who suffer from one of these disorders are never diagnosed, while the 
remaining 20%, though diagnosed, may or may not receive treatment (Healthline, 2017).  In 
addition, Transport Canada has concluded approximately 6% of the population suffers from a 
mood disorder (Transport Canada, 2018b).  Their research concludes this same ratio exists among 
flight crews (Transport Canada, 2018b).  
Participants in this research study comprised of three groups.  Group I was a sampling 
from the FAA, ICAO, and selective ICAO State aviation authorities.  Group II comprised of 
participants from the U.S. pilot population.  Group III comprised of a non-aviation medical 
professional.  Groups I and III were invited to participate via phone or Skype interview.  In the   
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event of scheduling and time constraints, participants were offered the opportunity to respond in 
writing via survey questionnaire.  Group II participants were asked to take a voluntary and 
anonymous survey.  Survey questionnaires for groups I and II were stored on a personal 
password-protected computer.  Group III was invited to complete a survey questionnaire 
electronically.   
Organization of Data and Respondents 
Group I 
Data from Group I was evaluated based on a phone interview or survey questionnaire 
responses in addition to a given State’s medical certification standards.  Group I was comprised 
of a representative from the FAA, ICAO, and selective ICAO State aviation authorities.  
Responses were evaluated and compared using a descriptive statistical analysis.  Comparisons 
were made between each agency that participated and their responses (see Appendix B; see 
Appendix C; see Appendix F).  
Group I demographics comprised of representatives from the following aviation 
authorities and countries: 
1. The Civil Aviation Authority of the UK (CAA); 
2. The Civil Aviation Safety Authority (CASA) (Australia); 
3. The Directorate General for Civil Aviation (DGAC) (France); 
4. The Federal Aviation Administration (FAA) (United States); 
5. The International Civil Aviation Organization (ICAO) (headquartered in Montreal); 
6. The Luftfahrt-Bundesamt (LBA) (Germany); 
7. The Swedish Transport Agency (STA); and 




Group II responses were evaluated using a descriptive statistical analysis.  In addition, 
graphs were used to represent respondent answers in comparison to others who participated in the 
study.  Group II responses were anonymous with no identifying information.  A descriptive 
statistical analysis was used to compare responses to FAA certification standards.  Based on 2017 
FAA statistics, there were 609,306 valid pilot certificates issued in the U.S. (FAA, 2017d).  Using 
the reported population size, a confidence level of 95% that yields a Z-Score of 1.96, and an 
estimated margin of error with a value of 4, the researcher calculated that a sample size of 600 
participants would be required for this research study.  Participants were solicited from Oklahoma 
State University, Southeastern Oklahoma State University, the University of Oklahoma, 
Oklahoma Aviation, and Embry Riddle Aeronautical University’s (Daytona Beach campus) flight 
programs.  In addition, pilots were recruited through invitations to 100 corporate flight 
departments (two from each state), and professional pilot forums.  Participants were only required 
to hold a valid FAA pilot certificate.  Currency, type of certificates held, and experience were not 
a requirement to participate (see Appendix B; see Appendix D; see figure 15 in Appendix G).  
Group III 
Group III responses were evaluated using a descriptive statistical analysis.  Non-aviation 
medical professional responses were used as a comparison to medical standards and practices 
outside of aviation.  In addition, Group III participants were asked to evaluate the FAA’s survey 
questionnaire responses and provide additional information to help compare the difference in 
aviation and non-aviation medical standards.  Dr. Lacy Anderson was the point of contact for 





Group I Data Analysis: Aviation Authority Interview and Survey Questionnaires 
Eight aviation authorities were asked to preview the interview or survey questions and 
indicate whether a representative from each agency may be able to participate in the study.  All 
authorities responded they would be willing to participate in the study; however, four agencies 
proceeded to answer the survey questions and responded rather than indicating their ability to 
participate in the study.  Those agencies were the FAA, Transport Canada, the Civil Aviation 
Authority of the UK, and the Swedish Transport Agency.  Initial communications indicated that 
the remaining three agencies were also willing to participate.  A CASA representative indicated 
they would be able to participate via Skype interview.  However, due to time constraints, CASA, 
the DGCA, and the LBA were unable to respond to this research study.  A representative from the 
International Civil Aviation Organization (ICAO) responded in a telephone interview with the 
researcher.  
The Federal Aviation Administration (FAA) 
The Federal Aviation Administration (FAA) was asked to respond to ten questions 
regarding its certification process, to evaluate standards set by ICAO, and evaluate certification 
standards used by other ICAO States.  The survey questions focused on the FAA’s opinions 
regarding the following topics (see Appendix B; see Appendix C): 
1. The FAA’s past and current certification process of airmen diagnosed with, or 
suffering from, anxiety and/or depressive disorders, and/or taking an SSRI. 
2. Why did the FAA, if applicable, choose to change its opinion and the certification 
process for airmen diagnosed with, or suffering from, anxiety and/or depressive 
disorders, and/or taking an SSRI? 
3. What information does the FAA consider when making policy changes? 
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4. Are there options available to airmen should a specific medication or treatment 
option not be a viable solution for a given individual? 
5. Are there other factors for the FAA that may result in denial of a medical application 
even though that airmen met and complied with the application process? 
6. Does the FAA have policies in place to ensure airmen compliance with new 
standards? 
7. Does the FAA have an estimate of how many airmen are, or are not, complying with 
the certification standards? 
8. The FAA was asked to evaluate a statement from the Australian Civil Aviation 
Safety Authority regarding individuals that take medication for anxiety and/or 
depressive disorders are no more dangerous than those who have not been diagnosed 
with, nor suffer from, one of these disorders. 
9. The FAA asked to evaluate whether, in their opinion, the FAA’s certification 
standards were more or less restrictive than ICAO’s recommendations. 
10. Any additional comments or opinions. 
FAA survey questionnaire responses. 
On behalf of the FAA, Dr. Stephen Goodman, Deputy Federal Air Surgeon, provided the 
following responses to the ten survey questions via email (see figure 6 in Appendix F): 
1. “The basis for the determination was scoping in on the history of ‘mild depression’ 
and determining that no other medical or psychiatric conditions were present. And 
that current medication treatment was adequate. The time frame specified has been 




2. “The FAA medical officers and FAA psychiatrist determined, that based on case 
reports and personal clinical experience that the psychiatric condition and use of 
acceptable medications that had a low side-effect profile would not impact the safety 
of the National Airspace System.” 
3. “The FAA Aerospace Medicine program is science-based that relies upon evidence-
based medical literature and clinical experience to make its medical/managements 
decisions. We also rely upon consultant reviews and the national data base [SIC] of 
aircraft accidents to validate our medical determinations.” 
4. “The diagnosis and medications we determined could be used by aviators all are low 
risks conditions. And the medications approved have the lowest possible side-effect 
profile. We are not considering any other antidepressant medications at this time.” 
5. “The essence of a denial of an FAA airman medical certificate is based upon clinical 
review of the psychiatric history. If the individual under consideration does not meet 
the FAA published requirements or the approved psychiatric medication was 
discontinued that is not clinically explained and other psychiatric conditions or 
medical conditions are present, then the applicant will be denied.” 
6. “There is an active program that is managed by FAA Aerospace Medicine SSRI 
program medical personnel. The underpinnings of the program include educating the 
FAA Aviation Medical Examiners who are the first representatives of the FAA that 
interact with aviators. The reporting requirement stipulated in the program are 
published and clear. The information is provided in real time and medical 
determinations are made in real time. The overall process is always under review 
using QMS/SMS processes.” 
7. “We have no way of determining who is not complying with the program. However, 
after 7 years we have 500 aviators who have participated in the program. We 
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acknowledge that this is a fraction of the aviator population who most likely are 
flying with the condition and medications without our knowledge.” 
8. “The FAA Aerospace Medicine managers do not agree with the Australian CAA. We 
would not be granting special issuance medical certificates if we did not believe that 
the risk was close to that of the unaffected population.” 
9. “We have not evaluated their process.” 
10. “We have collaborated with the ICAO prior to adopting our current policy. This 
collaboration has led to ICAO adopting a recommended practice that is sufficiently 
flexible to allow case by case consideration of affected applicants” (S. Goodman, 
personal communication, November 8, 2017). 
FAA response data analysis. 
The FAA representative stated that the agency’s determination to change its 
standardization regarding anxiety, depression, and SSRI usage is not solely dependent on 
decisions made by other ICAO States, but rather in alignment with recommended standards and 
practices by ICAO.  However, past research studies indicated that the FAA considered viewpoints 
of multiple agencies and organizations when evaluating whether to revise its standards (Diamond, 
2018; FAA, 2010a).  While the FAA states they are unaware of how many airmen are complying 
with the current certification and reporting standards, past FAA research indicates that 
approximately 59% of airmen are not complying with FAA standards and are hiding their medical 
information from the FAA (Persaud & Bruggen, 2015).  
It is the FAA’s opinion that the four currently approved medications are appropriate and 
offer the lowest chance of side effects for airmen.  However, there are no provisions available for 
an airman who may not respond effectively to one of the four FAA-approved medications.  In 
addition, the FAA does not agree with Australian findings in that those individuals who take 
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medication for anxiety and/or depressive disorders are no more dangerous than those who have 
not been diagnosed with or suffer from a mood disorder.  However, while the Civil Aviation 
Safety Authority (CASA) has made this determination, they too require applicants to apply for a 
special issuance medical (Werfelman, 2008).  CASA certification standards are less restrictive 
than those of the FAA.  In addition, the FAA does not appear to be aware if its certification 
standards are more stringent than ICAO recommendations or other ICAO States certification 
standards.  Furthermore, the FAA can deny a pilot applicant who successfully met initial 
certification requirements if the FAA believes the applicant’s past psychiatric history raises safety 
concerns. 
The Civil Aviation Authority (CAA) of the UK 
The Civil Aviation Authority (CAA) of the UK was asked to respond to ten questions 
regarding its certification process, to evaluate standards set by ICAO, and evaluate certification 
standards used by other ICAO States.  The survey questions focused on the CAA’s opinions 
regarding the following topics (see Appendix B; see Appendix C): 
1. The FAA’s past and current certification process of airmen diagnosed with, or 
suffering from, anxiety and/or depressive disorders, and/or taking an SSRI. 
2. Why did the CAA, if applicable, choose to change its opinion and the certification 
process for airmen diagnosed with, or suffering from, anxiety and/or depressive 
disorders, and/or taking an SSRI? 
3. What information does the CAA consider when making policy changes? 
4. Are there options available to airmen should a specific medication or treatment 
option not be a viable solution for a given individual? 
5. Are there other factors for the CAA that may result in denial of a medical application 
even though that airmen met and complied with the application process? 
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6. Does the CAA have policies in place to ensure airmen compliance with new 
standards? 
7. Does the CAA have an estimate of how many airmen are, or are not, complying with 
the certification standards? 
8. The CAA was asked to evaluate a statement from ICAO regarding individuals that 
take medication for anxiety and/or depressive disorders pose no significant safety 
risks. 
9. The CAA was asked to evaluate whether, in their opinion, if CAA’s certification 
standards were more or less restrictive than ICAO’s recommendations. 
10. Any additional comments or opinions. 
CAA survey questionnaire responses. 
On behalf of the CAA, Dr.Sally Evans, Chief Medical Officer of the Safety and Airspace 
Regulation Group for the UK Civil Aviation Authority, provided the following responses via 
email (see figure 7 in Appendix F): 
1. “The UK CAA accepts Citalopram, Sertraline, Escitalopram as maintenance therapy 
for those pilots wishing to maintain their medical certification. This is in conjunction 
with psychiatric assessments, simulator checks and Medical Flight Tests dependent 
on the class of medical certification. An OML (Operational Multi Pilot) Limitation 
on the certificate is imposed until 6 months cessation of all treatment. The UK CAA 
does not make judgements [SIC] on other Aviation Authority certificatory decisions 
or their rationale behind their policy decisions.” 
2. “The UK CAA policy was amended 5 years ago when the EU Aircrew Regulation 
was implemented in the UK, permitting this policy.”  
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3. “Any change in UK CAA policy regarding medical certification is undertaken 
following review of new evidence and research that may indicate a change is 
appropriate, in conjunction with expert medical opinion in the field. Full 
consideration is given to rationale behind the policy being reviewed and aviation 
safety implications.” 
4. “Current acceptable SSRI by the UK CAA are Citalopram, Sertraline and 
Escitalopram as maintenance therapy. No other psychotropic medication is 
permitted.” 
5. “The guidance for medical certification can be found on our website: 
(https://www.caa.co.uk/Aeromedical-Examiners/Medical-standards/Pilots-
(EASA)/Conditions/Psychiatry/Psychiatry-guidance-material-GM/).  If an applicant 
does not meet the requirements for initial / renewal or revalidation then a medical 
certificate cannot be granted.” 
6. “The guidance on the website shows the steps an applicant should follow to ensure 
compliance. The AMEs and CAA Psychiatrists are aware of this guidance and 
support the applicant in the steps to gain certification if appropriate.” 
7. “It is for the applicant to notify their AME if there is any change in their medical fit 
status or medication regime. Any changes that are identified at a medical and have 
not been declared by the applicant are thoroughly investigated and action taken 
accordingly. Non-compliance estimates are not available.” 
8. “The ICAO website ‘Manual of Civil Aviation Medicine’: 
(https://www.icao.int/publications/Documents/8984_cons_en.pdf) 9.5.5 states:"…In 
recent years, the use of SSRI (selective serotonin re-uptake inhibitors) has become 
widespread and there is indication that such treatment, aimed at preventing a new 
depressive episode, may be compatible with flying duties in carefully selected and 
monitored cases”. We agree with this statement.” 
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9. “The UK CAA adheres to EU regulations and cannot comment on the standards in 
other ICAO states” (S. Evans, personal communication, January 10, 2018). 
CAA response data analysis. 
Dr. Evans’ responses to the survey questionnaire demonstrate similarities as well as 
distinct differences in certification standards from those of the FAA.  For example, while the 
CAA does not consider policy issued by other ICAO States in their decision-making process, they 
do review all current research and ICAO recommendations before implementing new policies; a 
policy the FAA stated they employ as well.  The CAA is similar to the FAA in that they only 
allow certain approved medications to used by certificated pilots.  The CAA is not opposed to 
making changes in policy pending the information is supported by proven research.  Therefore, 
while a provision does not exist for an applicant to use a non-approved medication, future 
research results may influence the CAA to change their current standards. 
One specific area the CAA differs from the FAA is regarding how the CAA views 
ICAO’s statement that individuals who are treated for anxiety or depression, when properly 
medicated and monitored, pose no significant safety risks within the flight environment.  The 
CAA agrees with ICAO’s statement which is also similar to the statement made by CASA.  The 
FAA was asked to evaluate CASA’s statement and not ICAO’s.  However, the FAA does not 
agree with these statements. 
Dr. Evans’ responses in this research study appear to align with her statements made in 
previous presentations.  Agencies must approach the topic of mental health with caution.  The 
likelihood does exist that without proper handling of the situation, individual pilots may be more 
prone to violate existing policy and not report receiving treatment for anxiety or depression 
(Werfelman, 2008).  Lastly, Dr. Evans did not mention if the CAA has estimates regarding how 
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many airmen are complying with its standards.  According to the CAA, airmen are expected and 
required to comply with all standards and policies. 
The International Civil Aviation Organization (ICAO) 
The International Civil Aviation Organization (ICAO) was contacted by the researcher 
and asked to respond to five questions regarding the certification process for airmen suffering 
from, or diagnosed with, anxiety, depression, and/or taking an SSRI.  An ICAO representative 
was invited to answer questions via telephone or Skype interview, and an ICAO representative 
responded in a telephone interview.  The interview questions focused on ICAO’s opinions 
regarding the following topics: 
1. Whether ICAO has an opinion regarding member State certification processes? 
2. How and when did ICAO decide to change the policy on the topic of mental health 
and pilots?  In addition, what considerations does ICAO make before implementing 
new policies and guidance? 
3. Whether ICAO offers guidance should States follow regarding what medications 
should be considered and approved. 
4. Does ICAO offer any guidance to States for or require states to demonstrate pilot 
compliance with regulations. 
5. Does ICAO maintain statistics pertaining to compliance for a given ICAO State.  
ICAO interview responses and analysis. 
Dr. Ansa Jordaan, Chief of Aviation Medicine for ICAO, explained the rulemaking 
process and ICAO opinions.  An audio recording of her responses was made and transcribed by 
the researcher.  Dr. Jordaan stated that the subject of pilot mental health is nothing short of being 
problematic at times primarily because mental health issues are highly complex.  There is no 
baseline for measuring mental health as there are with checking one’s blood pressure or 
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cholesterol levels.  Not every individual pilot will have similar positive results regarding 
treatment options.  ICAO roles and responsibilities for a given topic may be both regulatory in 
nature as well as advisory.  In addition, ICAO standards are compulsory, and ICAO States are 
required to comply with these standards.  However, States have the authority to determine 
whether they will implement ICAO recommended practices, and each State may set their own 
guidelines (A. Jordaan, personal communication, July 12, 2018). 
According to Dr. Jordaan (2018), before ICAO considers a topic such as mental health in 
aviation, ICAO may elect to evaluate a given subject on their own or take subjects under further 
consideration based on State recommendations.  For example, an ICAO State may indicate they 
have conducted research regarding mental health and propose further evaluation by ICAO for 
consideration regarding adopting a new policy or issuing recommended practices and procedures 
for other ICAO States.  Once ICAO has evaluated research from other States, ICAO may elect 
notify States of its intent to issue proposed rulemaking and guidance.  However, any proposal 
requires a vote from all ICAO representatives (A. Jordaan, personal communication, July 12, 
2018).   
ICAO may decide to create a workgroup comprised of industry experts and State 
representatives to research a given topic.  These groups then present their findings which will be 
reviewed by professional groups that may include international organizations such as the 
Aerospace Medical Association (AsMA), and the European Aviation Safety Agency (EASA).  
These professional groups evaluate the findings and make recommendations to ICAO for 
implementation.  That information will be evaluated, and a decision is made whether ICAO will 
implement or change current standards and recommendations.  Those changes are forwarded to a 
council who, if passed, will forward the information to the States for a response.  States will 
indicate whether they will comply, or how they might implement the procedures.  If responses are 
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favorable, then a final vote will be presented to State representatives on the measure (A. Jordaan, 
personal communication, July 12, 2018). 
According to Dr. Jordaan (2018), given the fact that every pilot may respond differently 
to a medication, ICAO does not offer guidance on which medications should be approved or 
recommended.  Instead, ICAO defers to each State to conduct its own research and make the 
decision as to which medication it may be willing to approve for airmen use.  Furthermore, ICAO 
does not offer any guidance in the event a given medication is not effective for an airman. This 
can add another layer of complication to the certification process and the understanding of mental 
health issues.  ICAO advises each State that one must understand the underlying reason a given 
medication was prescribed to an airman.  According to Dr. Jordaan, each State’s primary concern 
should be aviation safety and whether a prescribed medication can interfere with or reduce safety 
margins within the flight environment (A. Jordaan, personal communication, July 12, 2018). 
According to Dr. Jordaan (2018), when a State certifies an airman, they are testifying that 
individual will not jeopardize flight safety.  However, ICAO is willing to defer much of the 
certification process and standards to the States when making a final determination regarding the 
airmen certification process.  Some States have implemented additional requirements which are 
not ICAO recommendations.  For example, some States require airmen to receive regular 
psychiatric evaluations and follow-up exams even with the successful demonstration of a 
prescribed medication.  In addition, some States require either simulator or flight check to verify 
safety standards (A. Jordaan, personal communication, July 12, 2018). 
Dr. Jordaan stated that ICAO did not initially enforce, or require, States to demonstrate or 
provide percentages of compliance or treatment success rates of airmen.  However, in 2016, 
ICAO asked States to begin tracking statistical data to identify how many accident and incidents 
occurred as a direct result of an airman’s mental health and SSRI use.  ICAO has required States 
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to begin tracking data between 2018 and 2019.  ICAO also intends to use this data to conduct 
further research on the subject and unify certification standards at some point in the future (A. 
Jordaan, personal communication, July 12, 2018). 
Lastly, Dr. Jordaan stated BasicMed has presented new challenges in the certification 
process.  Europe, for example, now offers BasicMed which is similar to the program in the U.S.  
These programs have significant deficiencies in tracking and identifying pilots who have, or had, 
serious medical conditions.  Currently, there is no adequate way to track these pilots, and 
additional ICAO States are expected to adopt similar BasicMed programs (A. Jordaan, personal 
communication, July 12, 2018).  
Transport Canada 
Transport Canada was asked to respond to ten questions regarding its certification 
process, to evaluate standards set by ICAO, and evaluate certification standards used by other 
ICAO States. The survey questions focused on Transport Canada’s opinions regarding the 
following topics (see Appendix B; see Appendix C): 
1. The FAA’s past and current certification process of airmen diagnosed with, or 
suffering from, anxiety and/or depressive disorders, and/or taking an SSRI. 
2. Why did the Transport Canada, if applicable, choose to change its opinion and the 
certification process for airmen diagnosed with, or suffering from, anxiety and/or 
depressive disorders, and/or taking an SSRI? 
3. What information does Transport Canada consider when making policy changes? 
4. Are there options available to airmen should a specific medication or treatment 
option not be a viable solution for a given individual? 
5. Are there other factors for Transport Canada that may result in denial of a medical 
application even though that airmen met and complied with the application process? 
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6. Does Transport Canada have policies in place to ensure airmen compliance with new 
standards? 
7. Does Transport Canada have an estimate of how many airmen are, or are not, 
complying with the certification standards? 
8. Transport Canada was asked to evaluate a statement from ICAO regarding 
individuals that take medication for anxiety and/or depressive disorders pose no 
significant safety risks. 
9. Transport Canada was asked to evaluate whether, in their opinion, if Transport 
Canada’s certification standards were more or less restrictive than ICAO’s 
recommendations. 
10. Any additional comments or opinions. 
Transport Canada survey questionnaire responses. 
On behalf of Transport Canada, Dr. Edward Brook, Senior Consultant Civil Aviation 
Medicine Transport Canada, provided the following responses via email (see figure 8 in 
Appendix F): 
1. “Yes. Our guidelines state “initial applicants who are still on medications must be at 
a stable dose for at least 4 months without aeromedically significant symptoms/side 
effects before submitting a detailed report from their attending physician” 
2. “Although TC guidelines were published on-line [SIC] around 2010 we had 
considered and certificated some professional pilots (while taking an SSRI) for 
restricted flight (with an accompanying pilot) since at least 2004. One argument was 
that by then many pilots were already taking maintenance doses (sometimes for years 
after successful treatment of an acute depression) but not declaring this use since they 
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would be grounded until the current policy was adapted (a similar situation applied to 
those undergoing alcohol rehabilitation in the ‘80s).” 
3. “When TC changes a policy (such as treatment for anxiety and depression) prior to 
making a decision we consider our experience (including those cases brought before 
our AMRB -Aviation Medical Review Board) and convene workshops involving all 
of our aviation medical officers (who are aerospace medicine specialists) as well as 
relevant clinical practitioners. In addition, we review ICAO and international aviation 
medicine practice and guidance.” 
4. “When our guideline was published we were considering only Prozac (fluoxetine), 
Zoloft (sertraline), Wellbutrin (bupropion), Celexa (citalopram), and Ciprolex 
(escitalopram). Note that we never direct treatment but assess applicants ‘as they 
are’. We have since considered and approved some applicants using other 
medications (such as venlafaxine and duloxetine).” 
5. “TC will assess and reassess as necessary when the clinical state changes (or when 
our policy evolves).  If a pilot or ATC develops aeromedically significant symptoms 
(e.g depression) or side effects of medication (e.g. drowsiness) then they are 
prohibited from exercising the privileges of any license until we have re-assessed 
their case (see CAR 404.06 http://laws-lois.justice.gc.ca/eng/regulations/SOR-96-
433/page-51.html#h-406).” 
6. “To ensure that all certificated pilots comply with the required regulations regarding 
anxiety, depression, and SSRIs, TC carefully monitors the physician reports, 
simulator ride or operational assessment reports (in the case of professional 
pilots/ATC) and SSRI questionnaires that must be submitted in addition to the 




7. “Of the (approx. 100 currently) pilots and ATC recently assessed in the SSRI 
program a small number have been administratively suspended under CAR 404.04 
(http://laws-lois.justice.gc.ca/eng/regulations/SOR-96-433/page-50.html#h-404) 
when they have been delinquent in submitting required reports. Most of these have 
been re-instated [SIC] once the requested documents have been provided. Fewer have 
been re-assessed as unfit because their condition has deteriorated.  It is more difficult 
to estimate the number of aircrew who have failed to disclose relevant clinical 
information (including all medications taken) during their MERs. Sometimes these 
pilots/ATC may be reported by their own physicians as required when a medical 
condition is likely to constitute a hazard to aviation safety under the Aeronautics Act 
6.5 (http://laws-lois.justice.gc.ca/eng/acts/A-2/page-9.html#h-25).”  
8. “TC would agree that some pilots taking medication for anxiety and/or depressive 
disorders pose no significant safety risks, depending on the medication/side-effects, 
psychiatric history (e.g.  depression must be in stable remission after adequate 
treatment) and with careful (aviation) medical assessment.” 
9. “Since most ICAO states still ground most if not all aircrew using SSRIs for any 
reason TC is less restrictive in practice.  TC does this by assessing each applicant 
individually and applying appropriate flexibility in accordance with ICAO standard 
(Annex 1 — Personnel Licensing 1.2.4.9) and our own ‘flexibilty’ [SIC] regulation 
(CAR 404.04 http://laws-lois.justice.gc.ca/eng/regulations/SOR-96-433/page-
52.html#h-415).” 
10. “Canada was one of the first countries to permit antidepressant usage by professional 
pilots, and our experience supports continued use.  Civil Aviation Medicine (CAM) 
will consider individual circumstances and apply flexibility to allow certain 
applicants using SSRI anti-depressants to exercise the privileges of licensure (with 
certain limitations such as flying with an accompanying pilot).” 
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“Applicants must be at least three months on a stable dosage after the end of active 
treatment (normally for depression) with resolution of symptoms and without any 
significant side effects. Currently, acceptable medications are Prozac (fluoxetine), 
Zoloft (sertraline), Wellbutrin (bupropion), Celexa (citalopram), and Ciprolex [SIC] 
(escitalopram).” 
“Psychiatric reports are required initially with semi-annual updates until six months 
after cessation of medication to insure [SIC] stability. “ 
“Once a clinical report (and diagnosis) has be made by a psychiatrist then subsequent 
semi-annual reports may be made by a personal physician (including a CAME).  In 
any case these reports should provide details of any symptoms and medication side-
effects (until at least six months after cessation of medication to insure [SIC] 
stability).” 
“Monitoring also includes periodic confirmation of performance by means of either 
operational or simulator ride reports (PPC, LoFT etc) or a Cogscreen annually and an 
annual epidemiological questionnaire.” 
“If a pilot or ATC ever develop aeromedically significant symptoms (e.g. depression) 
or side effects of medication (e.g. drowsiness) then they must refrain from exercising 
the privileges of their license until we have re-assessed the case. A change in dosage 
or discontinuation of medication will also require a report from the attending 
physician or specialist and close monitoring for side effects or onset of significant 





Transport Canada response data analysis. 
Dr. Brook’s responses indicate that Transport Canada has a different approach than other 
ICAO States regarding pilots and mental health.  While Transport Canada reviews 
recommendations by ICAO, they also consider medical research and practices from the 
international community as well.  This differs from the FAA’s response in that the FAA only 
considers ICAO guidance and not policy or opinion from other ICAO states.   
While exact numbers are not available, Transport Canada acknowledges that some of 
their airmen have successfully been taking medications and receiving treatment options without 
notifying Transport Canada due to fear of being grounded by the agency.  In addition, some have 
received violations for not adhering to regulatory compliance requirements.  However, the agency 
hopes that these pilots will eventually come forward with the adoption of new policies and 
certification standards.  Transport Canada initially only approved Prozac, Zoloft, Wellbutrin, 
Celexa, and Cipralex for airmen use.  Dr. Brook also cautioned that the agency never directs 
treatment.  Instead, they evaluate conditions and recommendations made by the appropriate 
medical professional.  In some cases, medication outside of those currently approved by 
Transport Canada has been allowed within specific guidelines.  
Transport Canada believes their certification standards and policies are often less 
stringent than those of other ICAO States.  Many States still ground applicants for mood disorders 
and SSRI use even though those applicants may meet certification requirements.  This practice is 
similar to the FAA’s certification process in that should an applicant’s psychiatric history come in 
to question, the FAA may still deny that applicant’s medical application even though initial 
certification requirements have been met.  This is regardless of whether that applicant 
demonstrated a successful trial period of an approved medication.  While Transport Canada does 
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not entirely agree with ICAO’s statement of low-risk SSRI users, they do agree that some pilots 
pose a lower safety risk.   
Swedish Transport Agency (STA) 
The Swedish Transport Agency (STA) was asked to respond to ten questions regarding 
its certification process, to evaluate standards set by ICAO, and evaluate certification standards 
used by other ICAO States.  The survey questions focused on the STA’s opinions regarding the 
following topics (see Appendix B; see Appendix C). 
1. The FAA’s past and current certification process of airmen diagnosed with, or 
suffering from, anxiety and/or depressive disorders, and/or taking an SSRI. 
2. Why did the STA, if applicable, choose to change its opinion and the certification 
process for airmen diagnosed with, or suffering from, anxiety and/or depressive 
disorders, and/or taking an SSRI? 
3. What information does the STA consider when making policy changes? 
4. Are there options available to airmen should a specific medication or treatment 
option not be a viable solution for a given individual? 
5. Are there other factors for the STA that may result in denial of a medical application 
even though that airmen met and complied with the application process? 
6. Does the STA have policies in place to ensure airmen compliance with new 
standards? 
7. Does the STA have an estimate of how many airmen are, or are not, complying with 
the certification standards? 
8. The STA was asked to evaluate a statement from ICAO regarding individuals that 




9. The STA was asked to evaluate whether, in their opinion, if STA’s certification 
standards were more or less restrictive than ICAO’s recommendations. 
10. Any additional comments or opinions. 
STA survey questionnaire responses. 
 On behalf of the STA, Dr. Dag Lemming, Medical Assessor Deputy Head of Section for 
Aviation Personnel, was unable to answer all the survey questions.  However, he did provide the 
following responses (see figure 9 in Appendix F): 
”I do not share your opinion that FAA is more stringent making aeromedical assessments. 
In Europe we work closely together with EASA and interact with ongoing rulemaking activities 
in this field (after the Germanwings catastrophe). Professional pilots licenced [SIC] in Sweden 
suffering from depression are all thoroughly evaluated on an individual basis, usually also 
reviewed by our own (authority) expert in psychiatry. We require a cognitive assessment 
(Cogscreen) before return to duty can be considered. In some cases approval with medication can 
be granted after simulator check and with limitation OML” (D. Lemming, personal 
communication, January 2, 2018). 
 ”You should look at both the consolidated implementing rules (Part-MED) and the AMC 
+ GM. Psychiatry is MED.B.055 but will soon be renamed mental health. With this link you can 
find the EASA rules we work with in [SIC] Europe. We  also use national guidelines (together 
with Norway) and frequently follow the UK CAA flow charts. We are quite restrictive with 
moderate depressions, especially if there is a history of repeted [SIC] illness and require complete 
resolution of symtoms [SIC] + usually an observation time (3-6 months for professional pilots) 




STA response data analysis. 
While Dr. Lemming was unable to provide detailed responses to the survey 
questionnaire, it was in his opinion, and not that of the Swedish Transport Agency (STA), that the 
FAA’s certification standards were not more stringent than those of the ICAO or other ICAO 
States.  The STA bases their certification protocol from European standards and follows medical 
guidance issued by the Civil Aviation Authority of the UK.  Dr. Lemming stated that applicants 
are evaluated on a case-by-case basis and are often re-evaluated by an STA psychology expert.  
Should an applicant have moderate levels of depression, or a history of repeated illness, then the 
STA could be more restrictive in certifying that applicant.  While the STA follows guidance 
issued by the UK’s CAA, their practices appear to be more restrictive than those of the FAA and 
other ICAO States who participated in this research study.  
Group I Participant Mean Responses 
Each agency received questions relative to their organization, and a comparison was 
made between those responses and published certification standards.  The FAA responded that, in 
their opinion, their certification methods are more than adequate when compared to ICAO’s 
recommended practices and procedures.  Four agencies responded to the invitation to participate 
in this research study; however, the Swedish Transport Agency (STA) offered a brief opinion 
rather than provide answers to the interview/survey questions.  Of the three participating 
agencies, 66% stated they do not compare standards of other countries when making decisions to 
change policy.  Only Transport Canada stated they consider both ICAO and other ICAO State 
opinions before making decisions.  While the FAA indicated they do not consider other ICAO 
State information, research indicates that the FAA has considered Australia and other ICAO State 
opinions before making policy changes (FAA, 2010a). 
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In addition, 66% of the participating agencies stated that no alternative options exist for 
an applicant should a particular SSRI treatment option not be effective.  However, Transport 
Canada stated that while they use certain SSRIs that are approved for airmen, they would 
consider allowing an applicant to use another method of treatment with sufficient evidence 
supporting its safety and effectiveness.  The FAA was not asked to evaluate ICAO’s statement 
that airmen who take an SSRI will have no significant safety risk.  However, they were asked to 
evaluate a Civil Aviation Safety Authority (CASA) opinion that individuals taking SSRIs are no 
more dangerous than those who have not been diagnosed or treated with a disorder.  The FAA did 
not agree with this statement.   
Agency participants were asked to evaluate ICAO’s statement regarding SSRI medicated 
pilots and significant safety risks.  Approximately 33% agreed that airmen prescribed an SSRI 
may no longer be considered a safety risk while approximately 33% agreed with the statement 
only some of the time.  Of the three participating agencies, 66% stated that they have policies in 
place that encourage airmen to comply with current certification standards.  However, 66% of 
participants also stated that they have no effective means to ensure airmen compliance, and none 
of the agencies stated they have estimates of how many airmen are not complying with the 
standards.   
ICAO defers final authority of airman medical certification to the individual ICAO 
States, and ICAO regulations allow for each State to develop and implement more stringent 
standards.  ICAO issues recommended standards and practices for each State to use as guidance 
when developing standards; however, ICAO does not offer guidance regarding medication for 
mood disorders which includes the length of any demonstration period.  Beginning in 2018 or 
2019, ICAO will require States to share their statistical data with ICAO regarding airmen 
compliance and accident rates.  The primary reason for sharing data with ICAO is to unify the 
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certification process requirements for all ICAO States and determine what regulatory changes are 
necessary for global harmonization of policies.   
Group II Data Analysis: Survey Questionnaire 
Group II subjects were invited to participate in this research study and recruited from a 
variety of sources.  Based on 2017 FAA statistics, there were 609,306 valid pilot certificates 
issued in the U.S. (FAA, 2017d).  Using the reported population size, a confidence level of 95% 
that yields a Z-Score of 1.96, and an estimated margin of error with a value of 4, the researcher 
calculated that a sample size of 600 participants would be required for this research study.  
Survey questions comprised of yes or no responses and asked respondents to evaluate the 
following topics (see Appendix B; see Appendix D; see figure 14 & 15 in in Appendix G): 
1. Whether the respondent agreed to the adequacy of the FAA’s policy regarding pilot 
medical certification standards for anxiety and depression before 2010. 
2. Whether the respondent agreed to the adequacy of the FAA’s policy regarding pilot 
medical certification standards for anxiety and depression after 2010. 
3. Whether the respondent agreed to the adequacy of the FAA’s policy regarding pilot 
medical certification standards for anxiety and depression in 2015. 
4. Whether respondents agreed to, and were aware of, Australia’s research, views, and 
pilot medical certification standards for anxiety and depression as early as the 1980s.     
Approximately 1,570 invitations were issued to participate in the survey. Participants 
were solicited from Oklahoma State University, Southeastern Oklahoma State University, the 
University of Oklahoma, Oklahoma Aviation, and Embry Riddle Aeronautical’ s (Daytona Beach 
campus) flight programs.  In addition, pilots were recruited through invitations to 100 random 
corporate flight departments (two from each state), and three professional pilot forums.  Five 
invitations were sent to the flight schools.  One hundred email invitations were sent to a random 
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selection of corporate flight departments in the U.S.  Approximately 320 individuals viewed the 
survey invitation from propilotworld.com, approximately 520 from airlinepilotcentral.com, and 
approximately 630 from jetcareers.com.  A total of 148 respondents participated in the survey 
over 45 days (see figure 14 in Appendix G). 
Pilot Survey Questionnaire: Q1  
Prior to 2010, FAA regulation stated that pilots diagnosed with anxiety and/or depressive 
disorders were prohibited from exercising the privileges of pilot in command and obtaining a 
medical certificate.  This also applied to those who may be taking medication as a treatment 
option for this disorder.  In your opinion was this regulation adequate? 
Pilot survey questionnaire: Q1 response results. 
Figure 1.  Question 1 responses from pilot survey. 
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Pilot survey questionnaire: Q1 data analysis. 
A total of 148 subjects participated in the pilot survey questionnaire (see figure 1 above).  
However, 23 respondents skipped the first question.  Each question required a response before a 
participant could view the following question.  Therefore, those 23 individuals could not proceed 
and were directed to the end of the survey.  However, a respondent may begin the survey 
questionnaire and agree to the electronic consent statement which would direct them to the first 
question.  Because information was anonymous, there was no means to ensure the 23 respondents 
who elected to skip a question did not return to attempt the survey again. 
Of the 148 respondents that participated in the survey, 125 completed question number 
one (Q1).  Respondents were asked in their opinion if the FAA policy which prohibited 
individuals from flying and obtaining a medical certificate was adequate.  Approximately 69% 
(86 participants) responded no that the FAA’s policies were not adequate indicating those 
individuals did not agree with FAA views.  Approximately 31% (39 participants) indicated that in 
their opinion FAA policy before 2010 was more than adequate (see figure 1 above).  The results 
from survey question one (Q1) may be an indicator that most of the U.S. pilot group, in total, 
would also agree with this statement and find that the FAA policies were not adequate by 
prohibiting pilots from flying or obtaining a medical certificate due to suffering from a mood 
disorder (see figure 15 in Appendix G).  
Pilot Survey Questionnaire: Q2 
In 2010, the FAA changed their certification standards regarding anxiety, depression, and 
treatment options.  An applicant may be able to act as pilot in command and receive a medical 
waiver if one were to use an approved FAA medication.  Certification required an applicant to 
show demonstrated use of the medication under the supervision of a psychiatric care physician for 
a period of twelve months.  After twelve months an applicant may request a re-evaluation of their 
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medical application by the FAA.  An application could be approved or denied.  In your opinion, 
was this an adequate certification process? 
Pilot survey questionnaire: Q2 response results. 
Figure2.  Question 2 responses from pilot survey. 
Pilot survey questionnaire: Q2 data analysis. 
Of the 148 respondents that attempted the survey, 125 completed question two (Q2).  
Respondents were asked in their opinion if the FAA’s policy, which prohibited individuals from 
flying and obtaining a medical certificate, was adequate after 2010.  In many cases, an applicant 
was granted a medical certificate and could continue flying if certain conditions were met. 
Approximately 49% (61 participants) responded no that the FAA policies were not adequate 
indicating those individuals did not agree with FAA views (see figure 2 above).    
Approximately 51% (64 participants) indicated that, in their opinion, FAA policy after 
2010 was more than adequate (see figure 2 above).  The results from survey question two (Q2) 
may be an indicator that the U.S. pilot group, in total, could also be divided when evaluating this 
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statement.  Because the survey is anonymous, there was not an adequate determination to identify 
what the reasoning for a given opinion.  For example, it is unknown what the approximate 
number of individuals who participated in this study also suffer from a mood disorder (see figure 
15 in Appendix G).  
Pilot Survey Questionnaire: Q3 
In 2015, the FAA changed their certification standards regarding anxiety, depression, and 
treatment options.  An applicant might be able to act as pilot in command and receive a medical 
waiver if one were to use an approved FAA medication.  Certification required an applicant to 
show demonstrated use of the medication under the supervision of a psychiatric care physician.  
The demonstrated time frame was reduced from twelve to six months.  After six months an 
applicant may request a re-evaluation of their medical application by the FAA.  An application 
could be approved or denied.  In your opinion, is this an adequate certification process? 
Pilot survey questionnaire: Q3 response results. 
Figure 3.  Question 3 responses from pilot survey. 
Total Respondents: 125 


























ANSWER CHOICES RESPONSES 
     
 





Pilot survey questionnaire: Q3 data analysis. 
Of the 148 respondents that attempted the survey, 125 completed question three (Q3).  
Respondents were asked, in their opinion, if the FAA policy which prohibited individuals from 
flying and obtaining a medical certificate was adequate after 2015.  In many cases, an applicant 
was granted a medical certificate and could continue flying if certain conditions were met. 
Approximately 49% (61 participants) responded that the FAA policy was not adequate indicating 
those individuals did not agree with FAA views (see figure 3 above).  Approximately 51% (64 
participants) indicated that in their opinion FAA policy after 2015 was more than adequate (see 
figure 3 above).  The results from survey question three (Q3) may be an indicator that the U.S. 
pilot group, in total, could also be divided when evaluating this statement (see figure 15 in 
Appendix G).  
Pilot Survey Questionnaire: Q4 
As early as the 1980s, some ICAO States have allowed their pilots to use various 
medications to treat anxiety and/or depressive disorders.  Australia, for example, is one of these 
States.  Australia has a certification process that takes no more than thirty days.  Moreover, the 
Australian Aviation Authority has concluded that individuals taking medication for anxiety 
and/or depressive disorders are no more dangerous than those who have not been diagnosed with, 
nor suffer from, anxiety and/or depression.  Other ICAO States share a similar opinion with 
Australia regarding the certification process.  Based on this information, when comparing it to 
how the FAA certifies U.S. pilots, do you find these certification standards are more reasonable 





Pilot survey questionnaire: Q4 response results. 
Figure 4.  Question 4 responses from pilot survey. 
Pilot survey questionnaire: Q4 data analysis. 
Of the 148 respondents that attempted the survey, 124 completed question four (Q4) (see 
figure 4 above).  Respondents were asked to evaluate a statement made by the Civil Aviation 
Safety Authority (CASA) of Australia regarding the safety of airmen suffering from anxiety, 
depression, or taking medication.  CASA research studies have indicated that those individuals 
being treated for a disorder are no more dangerous than individuals who do not suffer from or 
have been diagnosed with any disorders.  ICAO and other ICAO States agree with the statement.  
In addition, participants were asked to compare this statement to the previous three questions 
regarding the FAA views on the subject before and after 2010.  Participants were asked that, after 
reading this statement, if they found the FAA’s current policy to be less reasonable than those of 
the international community. 
Total Respondents: 124 
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Approximately 69% (85 participants) agreed after reading the statement that FAA policy 
was less reasonable and most likely not in line with international views on the subject. 
Approximately 31% (39 participants) indicated that current FAA policy was not more restrictive 
and more likely comparable to the international consensus on the subject (see figure 4 above).  
The results from survey question four (Q4) may be an indicator that the U.S. pilot group, in total, 
could also agree with this statement (see figure 15 in Appendix G). 
Group II Participant Mean Responses 
Survey results from questions one (Q1) and four (Q4) indicate that most of the sample 
group found that FAA policy and views before 2010 were inadequate when certifying airmen 
suffering from a mood disorder (see figures 1 and 4).  In addition, when reviewing Australian and 
ICAO statements regarding the safety of airmen diagnosed with, and/or seeking treatment options 
for anxiety and/or depression, a majority of the sample group found FAA views to be less 
reasonable when compared to the international community.  In both cases, approximately 69% of 
the sample population found the FAA policies and views to be inadequate.  Respondents were 
asked to evaluate FAA policy changes before and after 2010.  In both instances, results were 
almost evenly split with approximately 51% of the group agreeing that FAA policy and views 
during this time were adequate, while approximately 49% disagreed (see figures 2 and 3).  
Group III Data Analysis: Survey Questionnaire 
Group III was comprised of one non-aviation medical professional who was asked to 
participate via telephone interview or survey questionnaire and evaluate the FAA’s responses to 
questions asked in this research study.  After reviewing FAA responses, the participating non-
aviation medical professional was asked to answer eight questions and provide their medical 
opinion regarding the FAA’s certification process of airmen who suffer from, or have been 
diagnosed with, anxiety, depression, and/or taking an SSRI.  In each instance, the participant was 
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asked to compare non-aviation medical standards and compare those standards to FAA responses 
when diagnosing patients.  The participant was asked to respond to the following questions (see 
Appendix B; see Appendix E): 
1. Whether they agreed with FAA responses. 
2. Whether in their professional opinion if the can determine why the FAA only allows 
four specific SSRIs for airmen. 
3. Are there benefits to only prescribing the four types of SSRIs the FAA approves? 
4. Would the type of vehicle, equipment, or machinery influence the decision prescribe 
a particular SSRI? 
5. If they agreed, in their professional opinion, that before 2010 the FAA was correct in 
prohibiting airmen from flying with a mood disorder and/or taking medication. 
6. If they agreed, in their professional opinion, that after 2010 the FAA was correct in 
requiring a 12-month demonstration period before certifying an airmen suffering 
from a mood disorder and/or taking medication. 
7. If they agreed, in their professional opinion, that after to 2015 the FAA was correct in 
reducing demonstration periods from twelve to six months prior to certifying an 
airmen suffering from a mood disorder and/or taking medication. 
8. Participants were asked to evaluate the 30-day demonstration period Australia 
requires for its pilots regarding certification after diagnosis and treatment for a mood 
disorder.  Participants were also asked to evaluate Australia’s statements that pilots 
being treated for a mood disorder were no more dangerous than those who did not 
suffer from, nor have been diagnosed with anxiety and/or depression.  In addition, 
participants were asked to evaluate whether, in their opinion, if the FAA’s 




Group III Survey Questionnaire Responses 
Dr. Lacy Anderson, an M.D. in family medicine, responded and participated in this 
research study via electronic and written communication.  Dr. Anderson provided the following 
transcribed responses (see figure 10 in Appendix F): 
1. “I agree that the shortened 6 month time frame is plenty of time to assess whether 
medication has improved anxiety and depressive symptoms.” 
2. “I believe there is some basis to approving the four SSRIs approved.  The four they 
have approved have a lower risk of sleepiness and fatigue.  However, I believe this 
list could be expanded to add others to the approved list.  There are some newer 
medications as well that should be safe (however, I personally prescribe these newer 
medications much less often due to cost).  Psychiatrists are much more likely to 
prescribe newer medications because patients seeing a psychiatrist are more likely to 
have tried and failed less expensive medications prescribed by a primary care 
doctor.” 
3. “The four SSRIs approved are all very safe and widely used.  I agree that these 
medications have a low side effect profile and generally work very well.  I think the 
list could be expanded” to add other SSRIs as well as SNRIs and Wellbutrin mmki.” 
4. “My decision to prescribe anxiety or depression medications would not be affected 
by someone operating heavy equipment, a motor vehicle, or anything lager than a 
passenger vehicle.  However, I do warn people of the side effects of medication 
inducting sedation.” 
5. “Prior to 2010, pilots were unlikely to seek medication for anxiety or depression, 
because they might lose their license to fly.  They often asked me about herbal 
supplements instead, such as Sr. John’s Wart (which has a potentially worse safety 
profile than SSRIs).  I understand the need to regulate medications the might cause 
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adverse effects to pilots, but I feel that pilots with uncontrolled depression or anxiety 
are a much riskier proposition.  Also, because anxiety and depression are often felt 
short-term (6 months or less) and are often situational due to life stressors such as 
death, illness, or divorce, the FAA regulation prior to 2010 seemed unrealistic and 
unfair.  Medication would often get symptoms under control in 4-6 weeks instead of 
waiting 6 months or so for symptoms to resolve on their own.” 
6. “I believe the certification process to approve a pilot to act as Pilot in Command is 
more than adequate with a 12-month psychiatry follow up.  I would not recommend 
the need for more than 12 months or care.” 
7. “I agree with the decision to reduce the time from 12 to 6 months for continued care.  
6 months is more than adequate time to determine whether a medication is effective 
and to determine if adverse side effects are present.” 
8. I think the FAA’s more stringent guidelines for pilots should be relaxed somewhat.  I 
think more medications should be considered safe to be used by pilots.  The time 
frame could also be shortened to 3-6 months of treatment for mild depressive 
symptoms.  I think that 30 days may be an inadequate amount of time to determine if 
therapy is working, so I think that more time should be given to determine efficacy” 
(L. Anderson, personal communication, July 16, 2018). 
Group III survey questionnaire data analysis. 
In evaluating Dr. Anderson’s responses, it appears that non-aviation medical 
professionals moderately agree with current practices in the aviation community.  For example, 
Dr. Anderson agrees that not all medications work for all patients, and a single medication cannot 
be considered a viable treatment option with every diagnosis.  In addition, Dr. Anderson agreed 
that the FAA reduction in demonstration time, implemented after 2010, was more appropriate for 
airmen.  While Dr. Anderson agreed that follow-up care is necessary, she did state that care 
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beyond 12 months was not necessary.  This statement agrees with prior research which indicates 
many mood disorders are often short-term and the need for long-term treatment options are often 
unnecessary (Persaud & Bruggen, 2015). 
Dr. Anderson agreed that the FAA is too stringent regarding their certification standards 
and that many of the SSRI medications that are currently available yield high success rates in 
treating mood disorders.  In addition, while the FAA is not willing to recognize or approve 
additional medications for airmen, the FAA should consider that other medications yield a low 
risk of side effects as well.  Only Transport Canada had a similar opinion and will consider other 
SSRI medications or treatment options should one of the approved medications or treatment 
methods be insufficient for a given individual (E. Brook, personal communication, December 1, 
2017).     
Lastly, Dr. Anderson does not agree with Australia’s shortened demonstration period of 
four weeks.  In her opinion, a three to four-month period is more than adequate to make proper 
dosage adjustments, change medications, and evaluate the potential for unwanted side effects.  
Nevertheless, prior research indicates that aviation medicine is specialized, and often non-
aviation medical professionals are not aware of additional safety risks, or how a given medication 
may affect an individual when flying an aircraft (Ross, Griffiths, Dear, Emonson, & Lambeth, 









The purpose of this research study was to evaluate the Federal Aviation Administration’s 
(FAA) medical certification standards for airmen suffering from, or diagnosed with anxiety, 
depression, and/or taking an SSRI.  FAA certification standards were compared to ICAO and 
other ICAO States to determine whether FAA views and certification procedures are more 
stringent than other States.  Before 2010, the FAA maintained a strict policy which prohibited an 
airman from obtaining a medical certificate if they have been diagnosed with or were taking an 
SSRI (FAA, 2010a).  However, in 2010 those certification standards changed, and the FAA began 
allowing airmen to seek treatment options for mood disorders (FAA, 2010a).  Some research has 
indicated that these new standards for an airman might have been too strict.  The FAA required 
those taking medication, or who have been diagnosed with a mood disorder to cease flying 
temporarily.  In addition, a given applicant was required to demonstrate continued use of a single-
dose FAA approved SSRI medication for a 12-month period before being reevaluated and 
considered for the issuance of a medical certificate (FAA, 2010a). 
Since 2010, the FAA has relaxed its certification standards.  Demonstration times were 
reduced to a 6-month period of a continued single-dose use of an FAA-approved SSRI 
medication (FAA, 2017b).  Research indicates that the FAA changed their certification process 
based on input from ICAO and other ICAO State research (FAA, 2010a).  The FAA believes its  
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current certification process is more than adequate (S. Goodman, personal communication, 
November 8, 2017).  However; the FAA has not revised its approved, and very selective, SSRI 
medication list. 
Differences in Research and Certification Standards 
An important issue discovered during this research study identified the lack of unification 
between ICAO States and certification standards.  In an interview with Dr. Ansa Jordaan (2018), 
she indicated that each State might create its own certification standards based on their research 
and local laws.  States are encouraged, but not required, to review other State research and 
certification standards before developing their own.  States are also encouraged to review ICAO 
recommendations and guidance in addition to reviewing industry research and recommendations.  
Dr. Jordaan stated that one of ICAO’s goals is unification between all States on an array of issues 
(A. Jordaan, personal communication, July 12, 2018).  
Another concern discovered during this research study was a discontinuity in FAA views.  
In 2010, the FAA issued a press release which stated they considered views from industry leaders 
such as ICAO, AsMA, the AOPA, and other ICAO States prior making policy changes (FAA, 
2010a).  The FAA issued guidance for special issuance of medical certificates for airmen and 
SSRI use during the same month as the press release.  In the guidance, the FAA stated they 
reviewed procedures and views of the U.S. Army, Transport Canada, ICAO, Australia (CASA), 
the ALPA, and others in making their decision to change policy (FAA, 2010a).  Recently, the 
AOPA published an article also citing that the FAA considers research and recommendations 
form AsMA, Transport Canada, Australia (CASA), ICAO, the AOPA, the ALPA, and the U.S. 
Army (Diamond, 2018).  However, despite these publications, the FAA indicated in this research 




Research Questions One and Two (RQ1 & RQ2) 
RQ1: Are the FAA’s certification standards for pilots suffering from anxiety and/or 
depressive disorders too stringent, limited, or outdated when compared to ICAO or other 
ICAO States?   
RQ2: In addition, are the FAA’s certification standards for pilots taking SSRIs as a 
treatment option for anxiety and/or depressive disorders too stringent, limited, or 
outdated when compared to ICAO or other ICAO States?   
Prior research indicated that initial FAA views regarding mood disorders were most 
likely too stringent especially when compared to other State opinions and ICAO guidance.  
However, the FAA was within its right to set its own certification guidelines and was under no 
obligation to be unified with ICAO or other States.  In 2010, the FAA strictly prohibited any 
airmen from obtaining a medical certificate or exercising the privileges of pilot in command 
(PIC) if they had been diagnosed with a mood disorder or were taking an SSRI medication (FAA, 
2010a).  In addition, should an airman discontinue use of medication, or no longer display 
symptoms of a mood disorder, they were required to receive a statement from their treating 
physician indicating the applicant was free of any symptoms and had successfully ceased 
medication for at least 90 days before reinstatement of flight status (FAA, 2010a). 
However, the FAA changed their viewpoint in 2010 citing ICAO, ICAO States, and other 
industry research as a factor in shifting its views and allowing airmen to obtain a medical 
certificate after being diagnosed with a mood disorder and/or while receiving treatment options 
(FAA, 2010a).  The FAA required a demonstration period of successful treatment for 12 months 
before considering certification for an applicant (FAA, 2010a).  After 2010, the FAA changed its 
views once again and reduced the demonstration period from 12 to six months (FAA, 2010a; 
FAA, 2017b).  This recent change was more aligned with other ICAO State certification 
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standards.  For example, Australia and New Zealand require a four-week demonstration period, 
while the UK and Transport Canada have similar demonstration periods between three to four 
months (CAA New Zealand, 2013; Presenter, Hutchinson, 2013; Ross, Griffiths, Dear, Emonson, 
& Lambeth, 2007; Transport Canada, 2018b).    
Furthermore, when the FAA changed its certification standards after 2010, the new 
guidelines were similar to those of ICAO and other ICAO States.  For example, the Civil 
Aviation Authority (CAA) of the UK will not certify pilots until four weeks after the cessation of 
symptoms (Presenter, Hutchinson, 2013).  However, this is not an indicator of how much time 
might pass before symptoms subside.  According to Dr. Lacy Anderson (2018), a patient taking 
an SSRI should plan on a three to four month waiting period to verify that all unwanted side 
effects have been identified, and the effectiveness of the treatment option can be evaluated by the 
physician (L. Anderson, personal communication, July 16, 2018).  In the opinion of the Swedish 
Transport Agency, the FAA’s certification standards are more than adequate after the 2010 
revisions (D. Lemming, personal communication, January 2, 2018) (see figure 9 in Appendix F).    
According to Transport Canada, ICAO, and Dr. Anderson other treatment options should 
be considered for an applicant.  While it is essential to understand the primary reason why 
medication is being prescribed, it is equally important to realize not all medications will be 
effective for everyone.  The medications approved by the FAA are standard choices among 
prescribers due to their effectiveness, low occurrence of side effects, and often a price point for 
individuals (L. Anderson, personal communication, July 16, 2018).  However, the FAA does not 
have contingency options should one of the four approved SSRI options be ineffective for airmen. 
Dr. Anthony Evans, former chief of Aviation Medicine Section at ICAO, and Dr. Sally 
Evans of the UK’s Civil Aviation Authority (CAA), concluded that creating policies aimed at 
effective treatment and monitoring airmen taking antidepressants is more effective than those 
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which penalize and ground pilots for seeking or requiring treatments (Werfelman, 2008).  Both 
ICAO and the UK have concluded that existing policies are more likely to result in pilots flying 
untreated or flying while failing to disclose medical issues (Werfelman, 2008).  Such restrictive 
policies could persuade more pilots to take unapproved medications while continuing to fly 
Werfelman, 2008).    
Interpretation of RQ1 and RQ2 Findings 
Analyzing FAA certification standards and views regarding pilots suffering from anxiety, 
depression, and/or taking an SSRI yielded two primary results.  Before and during 2010, the 
findings suggested that the FAA standards were not outdated or limited when compared to ICAO 
and other ICAO States.  By 2010, ICAO and other ICAO States were already considering a 
revision of medical certification standards, and some of these States were certifying airmen 
suffering from mood disorders.  In addition, research indicates that some ICAO State certification 
standards were more reasonable than the FAA standards, while some ICAO State certification 
standards were similar to FAA views.  Pilot survey results and non-aviation medical feedback 
from this research study indicated that the FAA standards were extremely limiting.   
After 2010, the FAA lowered the demonstration period for airmen by six months.  When 
comparing this revised FAA standard to other ICAO States, the researcher determined the FAA 
establishment of a six-month demonstration period was similar to other ICAO States.  In addition, 
Dr. Lacy Anderson agreed that the decreased time in the demonstration period was more than 
sufficient and reasonable.  
Regarding research question one (RQ1), the researcher concludes that based on 
comparisons with ICAO and other ICAO States, the FAA was not more restrictive in its 
certification standards before 2010.  In addition, the researcher concludes that the FAA is not 
more restrictive in its current certification standards when compared to ICAO and other ICAO 
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States.  Regarding research question two (RQ2), the researcher concludes based on comparisons 
with ICAO and most ICAO States that the FAA has similar viewpoints to those who participated 
in this research study regarding SSRI use and treatment options for mood disorders in airmen.  
However, when comparing these standards with Transport Canada, the researcher concludes that 
the FAA is limited in not allowing, or considering, alternative treatment options for those who 
may not benefit from one of the approved FAA medications. 
Research Question Three (RQ3) 
RQ3: Can medical professionals outside the FAA help support the adequacy or 
inadequacy of pilot certification standards for those suffering from anxiety, 
depression, or who are using SSRIs?   
Dr. Lacy Anderson (2018) provided insight regarding common practices for patients 
suffering from mood disorders and taking SSRIs.  In Dr. Anderson’s opinion, early FAA 
certification models were too stringent.  In addition, Dr. Anderson did not believe that psychiatric 
follow-up visits were necessary beyond 12 months.  However, at least one follow-up examination 
should take place after the airman is stabilized and responding well to treatment options.  
Research has indicated, and as noted by Dr. Anderson, that while symptoms of anxiety or 
depression may be chronic, they are often short-lived (L. Anderson, personal communication, 
July 16, 2018; Persaud & Bruggen, 2015). 
It is in Dr. Anderson’s opinion (2018) that the shorter certification time of six months 
was more reasonable regarding airmen treatment; however, Dr. Anderson did state that at least a 
three to four-month observation period was necessary for determining overall treatment 
effectiveness.  Dr. Anderson did indicate that FAA practices have caused pilots to seek alternative 
treatment options.  For example, some of Dr. Anderson’s patients have asked questions regarding 
homeopathic treatment options for anxiety or depression (L. Anderson, personal communication, 
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July 16, 2018).  The FAA’s Aviation Medicine Advisory Services indicated that pilots have 
anonymously notified them as well regarding seeking alternative treatment options to avoid 
disclosure to the FAA (Persaud & Bruggen, 2015).  Lastly, research indicates that social stigma 
may also affect how airmen pursue the FAA certification process (Bor, Field, & Scragg, 2002; 
Schomerus, Stolzenburg, & Angermeyer, 2015). 
Interpretation of RQ3 Findings 
The data results from research question three (RQ3) indicated that non-aviation medical 
doctors may not entirely agree with earlier FAA guidelines for airmen medical certification 
standards; however, non-aviation doctors may favor the FAA’s recent policy revision that 
reduced the certification period to six months.  Dr. Anderson (2018) did not indicate in her 
responses if the six-month certification time was excessive.  However, she did state that the new 
and revised timeframe was more reasonable.  Dr. Anderson did indicate that three to four months 
was an appropriate timeframe to identify any potential problems regarding the treatment of 
airmen.  This timeframe is similar to UK and Canadian certification standards (Presenter, 
Hutchinson, 2013; Transport Canada, 2018b).   
The researcher concludes that non-aviation medical doctors may not have agreed with 
earlier FAA medical certification standards.  However, non-aviation medical doctors may agree 
with the certification standards revised after 2010.  Yet, non-aviation medical professionals may 
not agree with the FAA’s limited views regarding the approval of only four SSRI medications.  
While these medications are known for their effectiveness and low risk of side effects, they may 
not be effective for every pilot diagnosed with a mood disorder.  Therefore, the FAA should be 





Research Question Four (RQ4) 
RQ4: How do those in the U.S. pilot population view FAA certification standards on the 
subject of SSRIs, anxiety, and depressive disorders?   
Pilot survey questions one and four (see figures 1 & 4) indicate most pilots who 
participated in the survey believe FAA certification standards before 2010 were too strict.  In 
addition, after reading statements from ICAO and Australia, most pilots (69%) who participated 
in the survey believed the FAA medical certification standards were more rigorous when 
compared to ICAO and other ICAO States certification standards.  Pilot survey questions two and 
three (see figures 2 & 3) asked participants to evaluate FAA demonstration periods from 2010 
and later.  Initially, the FAA required an applicant to demonstrate successful use of an approved 
SSRI for 12 months before being considered for a medical certificate.  After 2010, the FAA 
revised their certification standards and reduced the demonstration period to six months.  The 
participating pilots were evenly split in their responses regarding these two questions.  
Approximately 51% of pilots agreed that the FAA standards before and after 2010 were sufficient 
and reasonable, while 49% of the pilots disagreed and stated the standards were too lengthy and 
too strict. 
Interpretation of RQ4 Findings 
The responses to research question four (RQ4) indicated that most of the participating 
pilots agreed that FAA medical certification standards were too stringent; especially after 
evaluating Australian and ICAO statements regarding airmen, mood disorders, and SSRI use.  
While the results of the pilot survey regarding FAA views during and after 2010 varied, it is 
unknown to the researcher how many participating pilots: (1) were taking an SSRI; (2) have been 
denied a medical certificate; (3) have successfully obtained a medical waiver; (4) were taking 
non-approved medications; and/or (5) suffered from a mood disorder but elected not to seek 
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treatment options.  This research study did not evaluate these variables to determine whether one 
or more of them may have been a factor in a pilot’s responses.  The researcher concludes that the 
majority of the participants in this research study agree that FAA certification standards are too 
stringent.  However, while results were closer regarding survey questions two and three (see 
figures 2 and 3), most participants believed FAA certification standards revised in and after 2010 
were sufficient and reasonable. 
Researcher Remarks 
It is the opinion of the researcher that the initial FAA medical certification standards 
regarding airmen suffering from or diagnosed with, anxiety, depression, and/or taking an SSRI 
were too stringent initially.  Before 2010, FAA certification standards did not permit U.S. 
certificated pilots to fly if diagnosed with a mood disorder or taking an SSRI as a treatment 
option (FAA, 2010a).  During this time, other ICAO States did not allow their pilots to fly with a 
mood disorder or while taking SSRI medication.  Though ICAO began issuing guidance on the 
subject in the early 2000s, FAA standards were similar to other ICAO States. 
When the FAA changed its certification standards in 2010, the agency permitted pilots 
who suffered from mood disorders and/or taking an SSRI medication to fly an aircraft (FAA, 
2010a).  However, applicants were required to discontinue flying and demonstrate 12 months of 
continual and successful use of an FAA-approved medication before being considered for a 
medical certificate (FAA, 2010a).  Even though the FAA was willing to revise their certification 
standards, they were more stringent than some ICAO States (ICAO, 2008).  For example, 
Australia certification standards only required a four-week demonstration period (Ross, Griffiths, 
Dear, Emonson, & Lambeth, 2007).  Transport Canada required applicants to complete a three to 
four-month demonstration period before receiving medical certification (Transport Canada, 
2018b).  However, this was not true for all ICAO States.  The UK, for example, did not consider 
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allowing its airmen diagnosed with a mood disorder to obtain medical certification until 2012 
(Presenter, Hutchinson, 2013).    
After 2010, the FAA lowered its certification standards further and required pilots to 
demonstrate successful use of an FAA-approved medication for six months (FAA, 2017b).  This 
reduction in time indicated the FAA was more accepting of the commonality of anxiety and 
depression.  In addition, this reduction in time is similar to what general and psychiatric care 
professionals consider to be an acceptable standard.  However, the FAA is still only allowing 
approving four SSRI medications for pilots.  While the FAA maintains its stance regarding 
medication, ICAO States such as Transport Canada are receptive to the idea of approving 
additional medications providing an applicant can demonstrate safety protocol while operating an 
aircraft (E. Brook, personal communication, December 1, 2017). 
Recommendations 
The topic of mood disorders is complex let alone the complications associated with 
piloting an aircraft while having been diagnosed with a mood disorder.  There is limiting research 
on the topic of SSRI medication and the U.S. aviation industry.  Most research studies have been 
conducted in the international aviation community.  In addition, much of the specific research that 
is available is dated and not relevant to today’s ever-changing aviation industry.  
Dr. Ansa Jordaan (2018) from ICAO agrees that not enough research exists regarding 
how mood disorders affect pilots and aviation safety.  During the past several years, the 
certification standards from one ICAO State to the next have differed due to regional and cultural 
differences; however, ICAO seeks to unify the international community regarding the complex 
topic of mood disorders and certification standards.  This unification, in all reality, is still many 
years away.  Therefore, additional research studies are needed, and perhaps collaborative efforts 
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across multiple disciplines are necessary in order to unify certification standards globally (A. 
Jordaan, personal communication, July 12, 2018). 
The opinions of pilots regarding mood disorders are not likely to change anytime soon.  
Different aviation authorities, including the FAA and ICAO, believe if acceptable standards and 
procedures cannot be achievable, then most certificated pilots will likely continue to operate 
aircraft while taking unapproved medications, not seeking proper treatment options, or failing to 
disclose any mood disorders to the appropriate governing authority.  Ultimately, this will have a 
direct effect on flight safety.  The literature reviewed for this study confirms that pilots have 
sought alternative treatment options outside FAA guidance in order to circumnavigate the 
certification process (Transport Canada, 2018b).  Transport Canada reported cases in which 
airmen colluded with doctors in order to receive a prescription for an SSRI (Transport Canada, 
2018b).  Dr. Anthony Evans, former chief of Aviation Medicine Section at ICAO, and Dr. Sally 
Evans of the UK’s Civil Aviation Authority (CAA), concluded that creating policies aimed at 
effective treatment and monitoring pilots taking antidepressants is far better than those which 
penalize and ground pilots for seeking or requiring treatment (Werfelman, 2008).   
Recommendation 1 
While FAA certification standards are comparable to ICAO and other ICAO State 
recommendations, the researcher recommends the FAA conduct additional studies on the subject.  
In addition, the researcher recommends the FAA maintain open communication with ICAO and 
other ICAO States to share and receive information regarding pilots and mood disorders.  The 
researcher also recommends an improved tracking procedure regarding compliance, accident 
rates, and the effectiveness of treatment among airmen.  ICAO will require States to track safety 
data and compliance between 2018 or 2019.  However, they are unsure how detailed the 
information will be initially, or how each State will choose to track the information.  Therefore, a 
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unified system for data tracking should be implemented at the same time ICAO States begin to 
collect data (A. Jordaan, personal communication, July 12, 2018). 
Recommendation 2 
Prior research has indicated that in order to make more informed decisions, multiple 
disciplines need to work collaboratively to develop conclusions and recommendations when 
addressing aviation safety and psychological medications (Nicholson, 2003).  Aerospace and 
conventional medical practices are significantly different.  Those who practice aerospace 
medicine focus on the general safety and health of those operating in the flight environment, 
whereas general and psychiatric care practitioners may not understand the effects of medication 
and human physiology in flight (A. Jordaan, personal communication, July 12, 2018).  However, 
the researcher recommends future studies and contributions across multiple disciplines to achieve 
a safe and viable solution for treatment options.  While studies have been conducted regarding 
SSRI use and aviation safety, there has not been a significant amount of research conducted 
across multiple disciplines to demonstrate a definitive link whether SSRI use in airmen has any 
detrimental effects on aviation safety (Ross, Griffiths, Dear, Emonson, & Lambeth, 2007). 
Recommendation 3 
Dr. Ansa Jordaan (2018) noted that each ICAO State has its own authority to develop and 
implement certification standards and practices; however, ICAO recommends that each State 
should model their standards on ICAO guidance.  ICAO acknowledges that unification in 
standardization is one of the agency’s most significant challenges.  This is evident when 
examining certification guidelines for the different ICAO States (A. Jordaan, personal 
communication, July 12, 2018).  For example, the FAA requires pilots to demonstrate successful 
use of an approved medication for six months (FAA, 2010a), while Transport Canada requires 
applicants to demonstrate a successful use for three to four months (Transport Canada, 2018b).  
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Transport Canada and the Civil Aviation Authority (CAA) of the UK may require that an airman 
is evaluated with a simulator or flight check, while the U.S. and Australia have no such 
requirement.  Australia and New Zealand have the lowest demonstration periods of any State at 
only four weeks (Ross, Griffiths, Dear, Emonson, & Lambeth, 2007). 
Differences in certification standards pose significant challenges for ICAO with 
alternative certification programs such as BasicMed.  These programs are currently being used by 
a few countries and have known loopholes in the system.  ICAO has concerns that airmen 
certified with BasicMed will not be adequately tracked, and governing authorities may not 
understand the breadth of the medical condition for a given airman (A. Jordaan, personal 
communication, July 12, 2018).  Therefore, the researcher recommends that ICAO thoroughly 
review BasicMed, other alternative medical certification programs, and develop recommended 
standards and practices should States choose to implement an alternative certification program. 
Recommendation 4 
Anxiety and depression can have detrimental effects on an individual’s quality of life.  
Research has shown how debilitating mood disorders can be both personally and professionally.  
Due to the stressful nature of a pilot’s lifestyle, these individuals may be more susceptible to 
suffering from one of these disorders than those whose lives are not as hectic and more routine.  
Nonetheless, the commitment to safety is a top priority for any airmen, and it would be irrational 
for the public, or even those within the aviation community, to think that pilots would not be 
susceptible to mood disorders. 
Part of the healing process when suffering from a mood disorder is for the affected 
individual to understand they are not alone nor is their condition unique (Stoutt, n.d.).  However, 
due to past regulations, industry stigma, and public perceptions pilots may be more inclined to 
hide their conditions rather than seek viable treatment options.  Treatment options for pilots are 
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limited.  Even though approved medications are prescribed due to the low occurrence of side 
effects, research and medical professional statements confirm that treatment options are not a 
one-size-fits-all solution to mental health (L. Anderson, personal communication, July 16, 2018).   
Transport Canada, while having preferred SSRI medications, is not opposed to additional 
medications or treatment options if an applicant can demonstrate there are no significant risks to 
aviation safety (E. Brook, personal communication, December 1, 2017).  In addition, Dr. Lacy 
Anderson (2018) noted that newer medications are on the market that may be more effective than 
those currently approved by the FAA.  While general and psychiatric care practitioners do not 
consider whether a patient operates or a motor vehicle, heavy equipment, or flies an aircraft when 
prescribing a medication, they do inform the patient of the potential side effects (L. Anderson, 
personal communication, July 16, 2018).  In addition, research has shown that while some SSRIs 
are associated with fatigue, they are not known to be debilitating or to affect alertness and 
cognitive abilities of an individual (Paul, Gray, Love, & Lange, 2007). 
The researcher recommends the FAA consider additional medications or treatment 
options for applicants.  In addition, the FAA should consider modeling a program similar to 
Transport Canada.  For additional medications to be considered and accepted by the FAA, more 
research will be required.  ICAO does not offer guidance or recommendation to other ICAO 
States regarding medications.  Therefore, the researcher recommends that ICAO consider issuing 
further guidance for States that focuses on approving medications and viable treatment options.  
The researcher also recommends ICAO emphasize the importance of States reviewing research 
conducted by industry organizations such as AsMA, and other State research initiatives.  
Recommendation 5 
Information provided on pilot medical applications is voluntary.  In the U.S., the FAA is 
only aware of what medical conditions a pilot has or medications a pilot is taking because that 
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individual discloses the information.  Should an applicant choose to withhold information, then 
the FAA may not be aware of the pilot’s condition.  While the FAA, ICAO, and ICAO States are 
more open to the topic of mood disorders and treatment options, there are no adequate means to 
ensure pilots are complying with current regulations.  ICAO acknowledges this can become a 
serious problem.  Therefore, research studies and contributions across multiple disciplines in the 
international aviation community will be necessary to develop an effective tracking program for 
pilots.  However, a tracking program will only be effective if all individuals are required to 
comply with certification standards and disclose medical information to the appropriate 
governing authority.  Congressional hearings have identified problems with pilots falsifying 
medical records to retain flight privileges (Federal Aviation Administration’s Oversight of 
Falsified Airman Medical Certificate Applications, 2007).  However, cases were only discovered 
when information was cross-referenced with those applying for government disability aid 
(Federal Aviation Administration’s Oversight of Falsified Airman Medical Certificate 
Applications, 2007).   
Conclusion 
It may take several years to develop viable solutions to many of the issues and concerns 
presented in this research study.  For future success, it is the researcher’s opinion that the FAA 
will need to demonstrate more openness not only with internal changes, but in recommended 
practices from ICAO and other ICAO States.  Pilots have a fear of potentially losing medical and 
flight privileges which could bring an end to a career.  Thus, it is understandable that 
apprehension causes individuals to contemplate non-disclosure of medical information.  
The FAA, ICAO, and other ICAO States have always made the concerted effort to 
improve safety in the aviation industry.  These agencies continue to encourage pilots to come 
forward with known medical issues including mood disorders.  However, there has to be greater 
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assurances that the agencies are not solely interested in punishing individuals for suffering from 
any medical condition.  As noted by Dr. Anthony Evans and Dr. Sally Evans, creating policies 
aimed at effective treatment and monitoring those taking antidepressants is far better than those 
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Electronic Consent Form 
The purpose of this research study is to compare FAA medical certification standards for those 
suffering from anxiety, depression, or taking an SSRI and comparing those standards to other 
ICAO States. There are no questions pertaining to your medical history. You are not required to 
have been diagnosed with any of these conditions to participate in this survey. This is a research 
project being conducted by Jake Durham at Oklahoma State University. You are invited to 
participate in this research project because you are a U.S. registered pilot. 
 
Your participation in this research study is voluntary. You may choose not to participate. If you 
decide to participate in this research survey, you may withdraw at any time. If you decide not to 
participate in this study, or if you withdraw from participating at any time, you will not be 
penalized. 
 
The procedure involves filling out an online survey that will take approximately 1-5 minutes. 
Your responses will be anonymous, confidential, and we do not collect identifying information 
such as your name, medical history, email address, or IP address. The survey questions will be 
about your opinions regarding the FAA’s certification process. 
 
All data is stored in a password protected electronic format. To help protect your confidentiality, 
the surveys will not contain information that will personally identify you. The results of this study 
will be used for scholarly purposes only and may be shared with Oklahoma State University 
representatives. Information may be published. 
 
If you have any questions about the research study, please contact Jake Durham at 
jake.durham@okstate.edu or Dr. Timm Bliss at timm.bliss@okstate.edu. This research has been 
reviewed according to Oklahoma State University IRB procedures for research involving human 
subjects. 
• ELECTRONIC CONSENT: Please select your choice below. 
Clicking on the "agree" button below indicates that: 
o you have read the above information 
o you voluntarily agree to participate 
o you are at least 18 years of age 
o you are a U.S. registered pilot 
If you do not wish to participate in the research study, please decline participation by clicking on 
the "disagree" button. 
 
Jake Durham, M.S.  
Aviation Sciences Institute at Rose State College  
6420 SE 15th St  
Midwest City, OK 73110  
405.736.0222  
jake.durham@okstate.edu  
Dr. Timm Bliss  
Oklahoma State University  
318 Willard Hall  
Stillwater, OK 74078  
405.334.1206  
timm.bliss@okstate.edu  
Oklahoma State University - Institutional Review Board  
Office of University Research Compliance  
223 Scott Hall  





Sample Waiver of Documentation (Medical) 
 
The purpose of this research study is to compare FAA medical certification standards for those 
suffering from anxiety, depression, and/or taking an SSRI and comparing those standards to other 
ICAO States. This is a research project being conducted by Jake Durham at Oklahoma State 
University. Your participation in this research study is voluntary. You may choose not to 
participate.  
 
The procedure involves asking a representative of your organization to provide non-aviation 
medical opinions based on FAA, ICAO, other ICAO State responses.  In addition, public law 
pertaining to aeromedical certification standards will also be provided for comparison.  
Information provided via telephone interview, in-person interview, Skype, email, or other means 
of communication obtained for this research study may be reproduced and used for a doctoral 
dissertation.  If the organization representative prefers not to be identified in this study, the results 
can remain anonymous and reference to the organization would be used instead (e.g., “according 
to Integris Medical group…”). 
 
If you have any questions about the research study, please contact Jake Durham at 
jake.durham@okstate.edu or Dr. Timm Bliss at timm.bliss@okstate.edu. This research has been 
reviewed according to Oklahoma State University IRB procedures for research involving human 
subjects. If you do not wish to participate in the research study, please respond to this email 
indicating your request to remain anonymous or for results information not to be used. 
 
Jake Durham, M.S.  
Aviation Sciences Institute at Rose State 
College                                                     
6420 SE 15th St 
Midwest City, OK 73110 
405.736.0222 
jake.durham@okstate.edu 
Dr. Timm Bliss 
Oklahoma State University  
318 Willard Hall 





Oklahoma State University - Institutional Review Board 
Office of University Research Compliance  
223 Scott Hall 


















Sample Waiver of Documentation (Aviation Authority) 
 
The purpose of this research study is to compare FAA medical certification standards for those 
suffering from anxiety, depression, and/or taking an SSRI and comparing those standards to other 
ICAO States. This is a research project being conducted by Jake Durham at Oklahoma State 
University. Your participation in this research study is voluntary. You may choose not to 
participate.  
 
The procedure involves asking a representative of your organization to provide additional 
guidance pertaining to public policy for your agency regarding airmen certification standards for 
those suffering from anxiety, depression, and/or taking an SSRI.  Information provided via 
telephone interview, Skype, email, or other means of communication obtained for this research 
study may be reproduced and used for a doctoral dissertation.  If the agency representative prefers 
not to be identified in this study, the results can remain anonymous and reference to the agency 
would be used instead (e.g., “according to ICAO…”). 
 
If you have any questions about the research study, please contact Jake Durham at 
jake.durham@okstate.edu or Dr. Timm Bliss at timm.bliss@okstate.edu. This research has been 
reviewed according to Oklahoma State University IRB procedures for research involving human 
subjects. If you do not wish to participate in the research study, please respond to this email 
indicating your request to remain anonymous or for results information not to be used. 
 
 
Jake Durham, M.S.  
Aviation Sciences Institute at Rose State 
College  
6420 SE 15th St 
Midwest City, OK 73110 
405.736.0222 
jake.durham@okstate.edu 
Dr. Timm Bliss 
Oklahoma State University  
318 Willard Hall 




Oklahoma State University              
Institution Review Board 
Office of University Research Compliance 
223 Scott Hall 





Pilot Survey Questionnaire Invitation 
 
Emails to Flight Schools 
I am a doctoral student with Oklahoma State University and I am asking for your assistance with 
my dissertation research. My research focuses on the FAA’s certification process for pilots 
suffering from anxiety, depression, and/or taking an SSRI and comparing those standards to other 
ICAO States. My theory is the FAA certification process is more stringent than, and not as 
flexible as other nations. In addition, my theory is that U.S. registered pilots may not be aware of 
the current certification standards and sharing this information may be beneficial to others in the 
pilot community.  
At this time, I would like to extend an offer to take an anonymous four-question survey through 
the link provided. No personal information will be requested or collected, and the survey is 
voluntary. No questions will be asked pertaining to a participant’s medical history. In addition, no 
prior diagnosis of any aforementioned condition(s) are required to participate in this study. The 
approximate time to complete the survey is between 1-5 minutes. If able, please forward this 
invitation email to your students.   
 
This study complies with, and has been approved, for human studies through Oklahoma State 
University’s IRB.  Please feel free to contact me with any questions. 
 
Link to survey: 
https://www.surveymonkey.com/r/CMBSWD7 
Jake Durham, M.S.  
6420 SE 15th St  
Aviation Sciences Institute at Rose State College  
Midwest City, OK 73110  
405.736.0222  
jake.durham@okstate.edu   
Dr. Timm Bliss  
Oklahoma State University  
318 Willard Hall  
Stillwater, OK 74078  
405.334.1206  
timm.bliss@okstate.edu  
Oklahoma State University Institutional Review Board  
Office of University Research Compliance  
223 Scott Hall  









Emails to Corporate Flight Departments 
Greetings,  
 
I am a doctoral student with Oklahoma State University and I am asking for your assistance with 
my dissertation research.  Your flight department was selected at random as a potential 
participant in this study.  My research focuses on the FAA’s certification process for pilots 
suffering from anxiety, depression, and/or taking an SSRI and comparing those standards to other 
ICAO States. My theory is the FAA certification process is more stringent than, and not as 
flexible as other nations. In addition, my theory is that U.S. registered pilots may not be aware of 
the current certification standards and sharing this information may be beneficial to others in the 
pilot community.  
At this time, I would like to extend an offer to take an anonymous four-question survey through 
the link provided. No personal information will be requested or collected, and the survey is 
voluntary. No questions will be asked pertaining to a participant’s medical history. In addition, no 
prior diagnosis of any aforementioned condition(s) are required to participate in this study. The 
approximate time to complete the survey is between 1-5 minutes.  If able, could you please pass 
this invitation throughout your flight department.   
 
This study complies with, and has been approved, for human studies through Oklahoma State 
University’s IRB.  Please feel free to contact me with any questions. 
 
Link to survey: 
https://www.surveymonkey.com/r/CMBSWD7 
 
Jake Durham, M.S.  
Aviation Sciences Institute at Rose State College  
6420 SE 15th St  




Dr. Timm Bliss  
Oklahoma State University  
318 Willard Hall  
Stillwater, OK 74078  
405.334.1206  
timm.bliss@okstate.edu  
Oklahoma State University Institutional Review Board  
Office of University Research Compliance  
223 Scott Hall  








Invitations Posted to Professional Pilot Forums 
Greetings everyone, 
 
I am a doctoral student with Oklahoma State University and I am asking for your assistance with 
my dissertation research. My research focuses on the FAA’s certification process for pilots 
suffering from anxiety, depression, and/or taking an SSRI and comparing those standards to other 
ICAO States. My theory is the FAA certification process is more stringent than, and not as 
flexible as other nations. In addition, my theory is that U.S. registered pilots may not be aware of 
the current certification standards and sharing this information may be beneficial to others in the 
pilot community.  
 
At this time, I would like to extend an offer to take an anonymous four-question survey through 
the link provided. No personal information will be requested or collected, and the survey is 
voluntary. No questions will be asked pertaining to a participant’s medical history. In addition, no 
prior diagnosis of any aforementioned condition(s) are required to participate in this study. The 
only requirement is that participants are U.S. registered pilots (student pilots included). The 
approximate time to complete the survey is between 1-5 minutes. If able, please feel free to 
forward this invitation to any other contacts you feel may be interested in participating.  
 
This study complies with, and has been approved, for human studies through Oklahoma State 
University’s IRB. Please feel free to contact me with any questions. 
 
Link to survey: 
https://www.surveymonkey.com/r/CMBSWD7 
 
Jake Durham, M.S.  
Aviation Sciences Institute at Rose State College  
6420 SE 15th St  
Midwest City, OK 73110  
405.736.0222  
jake.durham@okstate.edu  
Dr. Timm Bliss  
Oklahoma State University  
318 Willard Hall  
Stillwater, OK 74078  
405.334.1206  
timm.bliss@okstate.edu  
Oklahoma State University  
Institutional Review Board  
Office of University Research Compliance  
223 Scott Hall  









Sample Email Request for General Medical Practitioner to Participate in Research 
Interview or Survey 
Greetings, 
I am a professor in the United States and currently working on my dissertation for the completion 
of my doctorate.  My research topic is regarding the FAA and ICAO standards for SSRI use in 
pilots.  While my focus is regarding U.S. pilots, I am comparing how non-aerospace medical 
professionals interpret the FAA’s use and views of SSRIs.   
I would like to ask if you are willing to participate in this research study, and provide your 
medical opinion based on the FAA’s responses and current medical industry standards for SSRI 
use?  I have eight questions I would like to ask either through phone interview, or if time does not 
permit, via email communication.  I can include a sample of the intended questions for review.  
Information provided would be replicated and used for my final research.  If you have any 
questions, please feel free to contact me. 
This study complies with and has been approved, for human studies through Oklahoma State 
University’s IRB.  
Jake Durham, M.S.  
Aviation Sciences Institute at Rose State College  
6420 SE 15th St  
Midwest City, OK 73110  
405.736.0222  
jake.durham@okstate.edu  
Dr. Timm Bliss  
Oklahoma State University  
318 Willard Hall  
Stillwater, OK 74078  
405.334.1206  
timm.bliss@okstate.edu  
Oklahoma State University - Institutional Review Board  
Office of University Research Compliance  
223 Scott Hall  






Sample Email Request for Foreign Government Agencies to Participate in Research 
Interview or Survey 
Greetings, 
I am a professor in the United States and currently working on my dissertation for the completion 
of my doctorate.  My research topic is regarding the FAA and ICAO standards for SSRI 
use.  While my focus is regarding U.S. pilots, I am comparing how other ICAO State certification 
standards compare to the U.S. and FAA’s.  My research focusses on the administrative side; 
however, my theory is that FAA certification standards are much more stringent when compared 
to ICAO and other ICAO States.  While I have ICAO’s medical guidance standards, I wanted to 
ask if there is someone within your organization that can answer a few questions regarding your 
certification standards and process?  I have ten questions I would like to ask either through phone 
interview, or if time does not permit, via email communication.  I can include a sample of the 
intended questions for review.   Answers are to assist in the clarification of public law within the 
organization.  Information provided would be replicated and used for my final research.  If you 
have any questions, please feel free to contact me. 
This study complies with and has been approved, for human studies through Oklahoma State 
University’s IRB.  
Jake Durham, M.S.  
Aviation Sciences Institute at Rose State College  
6420 SE 15th St  
Midwest City, OK 73110  
405.736.0222  
jake.durham@okstate.edu  
Dr. Timm Bliss  
Oklahoma State University  
318 Willard Hall  
Stillwater, OK 74078  
405.334.1206  
timm.bliss@okstate.edu  
Oklahoma State University - Institutional Review Board  
Office of University Research Compliance  
223 Scott Hall  





Sample FAA Email Invitation Request to Participate in Research Interview or Survey 
Greetings, 
I am a doctoral candidate with Oklahoma State University.  My research topic is focused on some 
of the regulatory and medical standards regarding SSRIs, anxiety, and depressive disorders in 
U.S. pilots.  I have a few questions I was hoping you can answer or at least point me in the right 
direction.  I have ten interview questions I would like to ask an authorized representative from the 
FAA either through telephone interview, or if time does not permit, email communication.  
Responses are regarding clarification of public law.  In addition, responses would be replicated 
for this research study.  I can include a sample of the intended questions for review.  If you have 
any questions, please feel free to contact me. 
This study complies with, and has been approved, for human studies through Oklahoma State 
University’s IRB.  
Jake Durham, M.S.  
Aviation Sciences Institute at Rose State College  
6420 SE 15th St  
Midwest City, OK 73110  
405.736.0222  
jake.durham@okstate.edu  
Dr. Timm Bliss  
Oklahoma State University  
318 Willard Hall  
Stillwater, OK 74078  
405.334.1206  
timm.bliss@okstate.edu  
Oklahoma State University - Institutional Review Board  
Office of University Research Compliance  
223 Scott Hall  






FAA, ICAO, AND ICAO STATE INTERVIEW/SURVEY QUESTIONNAIRES 
FAA Interview/Survey Questionnaire 
1. According to articles written, the FAA has relaxed their requirements from a twelve-
month certification process to six months for those suffering from anxiety and/or 
depressive disorders, and/or taking an SSRI.  What was the basis for shortening the 
certification time? Does the FAA believe this time frame is adequate, too relaxed, or 
too stringent? 
2. Prior to 2010, the FAA did not allow pilots to exercise privileges of an airman 
certificate and medical if one was diagnosed with anxiety, depression, and/or taking 
an SSRI.  Why did the FAA make the decision to change its view on the subject? 
3. When the FAA makes the determination to change policy on a subject, such as 
anxiety and depressive disorders, what information does the FAA consider prior to 
making its decision? 
4. Currently the FAA has only approved four SSRI medications: (1) Lexapro; (2) 
Prozac; (3) Celexa; and (4) Zoloft.  There are many other SSRIs on the market such 
as Paxil, NDRIs such as Wellbutrin, SNRIs such as Cymbalta, or some next 
generation mediations such as Buspar.  Why have only the first four medications 
received approval by the FAA?  What options are available for an applicant if one of 




5. Once an applicant has successfully met the certification requirement and 
demonstrated acceptable usage of an SSRI the Federal Air Surgeon may then, at their 
discretion, issue a waiver allowing for the issuance of a medical certificate to an 
applicant.  What are the primary reasons for declining a waiver even if the applicant 
has successfully met all the initial requirements?  
6. What is the FAA doing to ensure that all certificated pilots in the U.S. comply with 
the required regulations regarding anxiety, depression, and SSRIs? 
7. Does the FAA have estimates of how many U.S. pilots are not complying with the 
required regulations regarding anxiety, depression, and SSRIs? 
8. The Australian Civil Aviation Safety Authority has concluded that individuals taking 
medication for anxiety and/or depressive disorders are no more dangerous than those 
who have not been diagnosed with, nor suffer from, one of these disorders.  Does the 
FAA agree with this statement? 
9. When comparing FAA pilot certification standards for anxiety, depression, and/or 
SSRI use to those of ICAO or ICAO States, does the FAA find ICAO standards to be 
less effective or less restrictive than theirs? 
10. Any additional comments? 
Transport Canada Interview/Survey Questionnaire 
1. According to articles written, the FAA has relaxed their requirements from a twelve-
month certification process to six months for those suffering from anxiety and/or 
depressive disorders, and/or taking an SSRI.  This is a demonstration period under 
doctor supervision.  Does Transport Canada think this is an adequate time frame, 
excessive, or too stringent of a certification process? 
2. When did Transport Canada decide they would allow pilots to exercise privileges of 
an airman certificate and medical if one was diagnosed with anxiety, depression, 
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and/or taking an SSRI?  Why did Transport Canada make the decision to change its 
view on the subject? 
3. When Transport Canada makes the determination to change policy on a subject, such 
as anxiety and depressive disorders, what information does Transport Canada 
consider prior to making its decision? 
4. Each ICAO State varies slightly in the medications that are approved to take for those 
suffering from, or diagnosed with, anxiety and/or depressive disorders.  For example, 
the FAA has only approved four SSRI medications: (1) Lexapro; (2) Prozac; (3) 
Celexa; and (4) Zoloft.  What options are available for an applicant if one of the 
medications approved by Transport Canada are not an effective treatment option? 
5. What are the primary reasons Transport Canada may decline an application for a 
medical even after an applicant has successfully met all the initial requirements?  
6. What is Transport Canada doing to ensure that all certificated pilots comply with the 
required regulations regarding anxiety, depression, and SSRIs? 
7. Does Transport Canada have estimates of how many pilots are not complying with 
the required regulations regarding anxiety, depression, and SSRIs? 
8. ICAO has concluded that pilots taking medication for anxiety and/or depressive 
disorders pose no significant safety risks.  Does Transport Canada agree with this 
statement? 
9. When comparing Transport Canada pilot certification standards for anxiety, 
depression, and/or SSRI use to those of ICAO or ICAO States, does Transport 
Canada find ICAO standards to be less effective or less restrictive than theirs? 





UK Civil Aviation Authority Interview/Survey Questionnaire 
1. According to articles written, the FAA has relaxed their requirements from a twelve-
month certification process to six months for those suffering from anxiety and/or 
depressive disorders, and/or taking an SSRI.  This is a demonstration period under 
doctor supervision.  Does the UK Civil Aviation Authority think this is an adequate 
time frame, excessive, or too stringent of a certification process? 
2. When did the UK Civil Aviation Authority decide they would allow pilots to exercise 
privileges of an airman certificate and medical if one was diagnosed with anxiety, 
depression, and/or taking an SSRI?  Why did the Civil Aviation Authority make the 
decision to change its view on the subject? 
3. When the UK Civil Aviation Authority makes the determination to change policy on 
a subject, such as anxiety and depressive disorders, what information does the CAA 
consider prior to making its decision? 
4. Each ICAO State varies slightly in the medications that are approved to take for those 
suffering from, or diagnosed with, anxiety and/or depressive disorders.  For example, 
the FAA has only approved four SSRI medications: (1) Lexapro; (2) Prozac; (3) 
Celexa; and (4) Zoloft.  What options are available for an applicant if one of the 
medications approved by the UK Civil Aviation Authority are not an effective 
treatment option? 
5. What are the primary reasons the UK Civil Aviation Authority may decline an 
application for a medical even after an applicant has successfully met all the initial 
requirements?  
6. What is the UK Civil Aviation Authority doing to ensure that all certificated pilots 
comply with the required regulations regarding anxiety, depression, and SSRIs? 
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7. Does the UK Civil Aviation Authority have estimates of how many pilots are not 
complying with the required regulations regarding anxiety, depression, and SSRIs? 
8. ICAO has concluded that pilots taking medication for anxiety and/or depressive 
disorders pose no significant safety risks.  Does the UK Civil Aviation Authority 
agree with this statement? 
9. When comparing the UK Civil Aviation Authority pilot certification standards for 
anxiety, depression, and/or SSRI use to those of ICAO or ICAO States, the CAA find 
ICAO standards to be less effective or less restrictive than theirs? 
10. Any additional comments? 
The Civil Aviation Safety Authority of Australia (CASA) Interview/Survey Questionnaire 
1. According to articles written, the FAA has relaxed their requirements from a twelve-
month certification process to six months for those suffering from anxiety and/or 
depressive disorders, and/or taking an SSRI.  This is a demonstration period under 
doctor supervision.  Does CASA think this is an adequate time frame, excessive, or 
too stringent of a certification process? 
2. When did CASA decide they would allow pilots to exercise privileges of an airman 
certificate and medical if one was diagnosed with anxiety, depression, and/or taking 
an SSRI?  Why did CASA make the decision to change its view on the subject? 
3. When CASA makes the determination to change policy on a subject, such as anxiety 
and depressive disorders, what information does CASA consider prior to making its 
decision? 
4. Each ICAO State varies slightly in the medications that are approved to take for those 
suffering from, or diagnosed with, anxiety and/or depressive disorders.  For example, 
the FAA has only approved four SSRI medications: (1) Lexapro; (2) Prozac; (3) 
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Celexa; and (4) Zoloft.  What options are available for an applicant if one of the 
medications approved by CASA are not an effective treatment option? 
5. What are the primary reasons CASA may decline an application for a medical even 
after an applicant has successfully met all the initial requirements?  
6. What is CASA doing to ensure that all certificated pilots comply with the required 
regulations regarding anxiety, depression, and SSRIs? 
7. Does CASA have estimates of how many pilots are not complying with the required 
regulations regarding anxiety, depression, and SSRIs? 
8. ICAO has concluded that pilots taking medication for anxiety and/or depressive 
disorders pose no significant safety risks.  Does CASA agree with this statement? 
9. When comparing CASA pilot certification standards for anxiety, depression, and/or 
SSRI use to those of ICAO or ICAO States, does CASA find ICAO standards to be 
less effective or less restrictive than theirs? 
10. Any additional comments? 
German Civil Aviation Authority (Luftfahrt-Bundesamt (LBA)) Interview/Survey 
Questionnaire 
1. According to articles written, the FAA has relaxed their requirements from a twelve-
month certification process to six months for those suffering from anxiety and/or 
depressive disorders, and/or taking an SSRI.  This is a demonstration period under 
doctor supervision.  Does the LBA think this is an adequate time frame, excessive, or 
too stringent of a certification process? 
2. When did the LBA decide they would allow pilots to exercise privileges of an airman 
certificate and medical if one was diagnosed with anxiety, depression, and/or taking 
an SSRI?  Why did the LBA make the decision to change its view on the subject? 
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3. When the LBA makes the determination to change policy on a subject, such as 
anxiety and depressive disorders, what information does the LBA consider prior to 
making its decision? 
4. Each ICAO State varies slightly in the medications that are approved to take for those 
suffering from, or diagnosed with, anxiety and/or depressive disorders.  For example, 
the FAA has only approved four SSRI medications: (1) Lexapro; (2) Prozac; (3) 
Celexa; and (4) Zoloft.  What options are available for an applicant if one of the 
medications approved by the LBA are not an effective treatment option? 
5. What are the primary reasons the LBA may decline an application for a medical even 
after an applicant has successfully met all the initial requirements?  
6. What is the LBA doing to ensure that all certificated pilots comply with the required 
regulations regarding anxiety, depression, and SSRIs? 
7. Does the LBA have estimates of how many pilots are not complying with the 
required regulations regarding anxiety, depression, and SSRIs? 
8. ICAO has concluded that pilots taking medication for anxiety and/or depressive 
disorders pose no significant safety risks.  Does the LBA agree with this statement? 
9. When comparing LBA pilot certification standards for anxiety, depression, and/or 
SSRI use to those of ICAO or ICAO States, does the LBA find ICAO standards to be 
less effective or less restrictive than theirs? 
10. Any additional comments? 
French Civil Aviation Authority (The Directorate General for Civil Aviation (DGAC)) 
Interview/Survey Questionnaire 
1. According to articles written, the FAA has relaxed their requirements from a twelve-
month certification process to six months for those suffering from anxiety and/or 
depressive disorders, and/or taking an SSRI.  This is a demonstration period under 
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doctor supervision.  Does the DGAC think this is an adequate time frame, excessive, 
or too stringent of a certification process? 
2. When did the DGAC decide they would allow pilots to exercise privileges of an 
airman certificate and medical if one was diagnosed with anxiety, depression, and/or 
taking an SSRI?  Why did the DGAC make the decision to change its view on the 
subject? 
3. When the DGAC makes the determination to change a policy on a subject, such as 
anxiety and depressive disorders, what information does the DGAC consider prior to 
making its decision? 
4. Each ICAO State varies slightly in the medications that are approved to take for those 
suffering from, or diagnosed with, anxiety and/or depressive disorders.  For example, 
the FAA has only approved four SSRI medications: (1) Lexapro; (2) Prozac; (3) 
Celexa; and (4) Zoloft.  What options are available for an applicant if one of the 
medications approved by the DGAC are not an effective treatment option? 
5. What are the primary reasons the DGAC may decline an application for a medical 
even after an applicant has successfully met all the initial requirements?  
6. What is the DGAC doing to ensure that all certificated pilots comply with the 
required regulations regarding anxiety, depression, and SSRIs? 
7. Does the DGAC have estimates of how many pilots are not complying with the 
required regulations regarding anxiety, depression, and SSRIs? 
8. ICAO has concluded that pilots taking medication for anxiety and/or depressive 
disorders pose no significant safety risks.  Does the DGAC agree with this statement? 
9. When comparing DGAC pilot certification standards for anxiety, depression, and/or 
SSRI use to those of ICAO or ICAO States, does the DGAC find ICAO standards to 
be less effective or less restrictive than theirs? 
10. Any additional comments? 
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Swedish Transport Agency (STA) Interview/Survey Questionnaire 
1. According to articles written, the FAA has relaxed their requirements from a twelve-
month certification process to six months for those suffering from anxiety and/or 
depressive disorders, and/or taking an SSRI.  This is a demonstration period under 
doctor supervision.  Does the STA (Swedish Transport Agency) think this is an 
adequate time frame, excessive, or too stringent of a certification process? 
2. When did the STA (Swedish Transport Agency) decide they would allow pilots to 
exercise privileges of an airman certificate and medical if one was diagnosed with 
anxiety, depression, and/or taking an SSRI?  Why did the STA (Swedish Transport 
Agency) make the decision to change its view on the subject? 
3. When the STA (Swedish Transport Agency) makes the determination to change 
policy on a subject, such as anxiety and depressive disorders, what information does 
the STA (Swedish Transport Agency) consider prior to making its decision? 
4. Each ICAO State varies slightly in the medications that are approved to take for those 
suffering from, or diagnosed with, anxiety and/or depressive disorders.  For example, 
the FAA has only approved four SSRI medications: (1) Lexapro; (2) Prozac; (3) 
Celexa; and (4) Zoloft.  What options are available for an applicant if one of the 
medications approved by the STA (Swedish Transport Agency) are not an effective 
treatment option? 
5. What are the primary reasons the STA (Swedish Transport Agency) may decline an 
application for a medical even after an applicant has successfully met all the initial 
requirements?  
6. What is the STA (Swedish Transport Agency) doing to ensure that all certificated 




7. Does the STA (Swedish Transport Agency) have estimates of how many pilots are 
not complying with the required regulations regarding anxiety, depression, and 
SSRIs? 
8. ICAO has concluded that pilots taking medication for anxiety and/or depressive 
disorders pose no significant safety risks.  Does the STA (Swedish Transport 
Agency) agree with this statement? 
9. When comparing STA (Swedish Transport Agency) pilot certification standards for 
anxiety, depression, and/or SSRI use to those of ICAO or ICAO States, does the STA 
(Swedish Transport Agency) find ICAO standards to be less effective or less 
restrictive than theirs? 
10. Any additional comments? 
International Civil Aviation Organization (ICAO) Interview/Survey Questionnaire 
1. According to articles written, the FAA has relaxed their requirements from a twelve-
month certification process to six months for those suffering from anxiety and/or 
depressive disorders, and/or taking an SSRI.  This is a demonstration period under 
doctor supervision.  Does ICAO think this is an adequate time frame, excessive, or 
too stringent of a certification process? 
2. When did ICAO did decide they would allow pilots to exercise privileges of an 
airman certificate and medical if one was diagnosed with anxiety, depression, and/or 
taking an SSRI?  Why did ICAO make the decision to change its view on the 
subject? 
3. When ICAO makes the determination to change a policy on a subject, such as anxiety 




4. Each ICAO State varies slightly in the medications that are approved to take for those 
suffering from, or diagnosed with, anxiety and/or depressive disorders.  For example, 
the FAA has only approved four SSRI medications: (1) Lexapro; (2) Prozac; (3) 
Celexa; and (4) Zoloft.  What options are available for an applicant if one of the 
medications approved by an ICAO State are not an effective treatment option? 
5. What are the primary reasons ICAO States may decline an application for a medical 
even after an applicant has successfully met all the initial requirements?  
6. What is ICAO doing to ensure that all certificated pilots comply with the required 
regulations regarding anxiety, depression, and SSRIs? 
7. Does the ICAO have estimates of how many pilots are not complying with the 
required regulations regarding anxiety, depression, and SSRIs? 
8. ICAO has concluded that pilots taking medication for anxiety and/or depressive 
disorders pose no significant safety risks.  Does ICAO agree with this statement? 




PILOT SURVEY QUESTIONNAIRE 
1. Prior to 2010, FAA regulation stated that pilots diagnosed with an anxiety and/or 
depressive disorders were prohibited from exercising the privileges of Pilot in 
Command and obtaining a medical certificate.  This also applied to those who may be 
taking medication as a treatment option for this disorder.  In your opinion was this 
regulation adequate? 
[   ] Yes [   ] No 
2. In 2010, the FAA changed their certification standards regarding anxiety, depression, 
and treatment options.  An applicant may be able to act as Pilot in Command and 
receive a medical waiver if one were to use an approved FAA medication.  
Certification required an applicant to show demonstrated use of the medication under 
supervision of a psychiatric care physician for a period of twelve months.  After 
twelve months an applicant may request a re-evaluation of their medical application 
by the FAA.  An application could be approved or denied.  In your opinion, was this 
an adequate certification process? 




3. In 2015, the FAA changed their certification standards regarding anxiety, depression, 
and treatment options.  An applicant may be able to act as Pilot in Command and 
receive a medical waiver if one were to use an approved FAA medication.  
Certification required an applicant to show demonstrated use of the medication under 
supervision of a psychiatric care physician.  The demonstrated time frame was 
reduced from twelve to six months.  After six months an applicant may request a re-
evaluation of their medical application by the FAA.  An application could be 
approved or denied.  In your opinion, is this an adequate certification process? 
a. [   ] Yes [   ] No  
4. As early as the 1980s, some ICAO States have allowed their pilots to use various 
medications to treat anxiety and/or depressive disorders.  Australia for example is one 
of these States.  Australia has a certification process that takes no more than thirty 
days.  Moreover, the Australian Aviation Authority has concluded that individuals 
taking medication for anxiety and/or depressive disorders are no more dangerous than 
those who have not been diagnosed with, nor suffer from, anxiety and/or depression.  
Other ICAO States share a similar opinion with Australia regarding the certification 
process.  Based on this information, when comparing it to how the FAA certifies U.S. 
pilots, do you find these certification standards are more reasonable than the FAA’s? 




NON-AVIATION MEDICAL PROFESSIONAL INVERVIEW/SURVEY 
QUESTIONNAIRE 
Non-Aviation Medical Professional Interview/Survey Questionnaire     
(Completed after FAA interviews) 
1. Based on the information given by the FAA regarding anxiety, depression, and SSRI 
usage, do you agree or disagree with their viewpoints? 
2. In your professional opinion, is there any basis regarding the FAA’s decision to only 
approve four SSRIs; (1) Lexapro; (2) Prozac; (3) Celexa; and (4) Zoloft? 
3. In your professional opinion, are there benefits to prescribing these four SSRIs as 
opposed to other medications prescribed for anxiety and/or depressive disorders? 
4. Would your decision to prescribe one of the four mentioned SSRIs, or any other 
medication, for anxiety and/or depressive disorders, be affected based on if a patient: 
a. Operates heavy equipment? 
b. Operates a motor vehicle? 
c. Operates anything larger than a passenger vehicle (e.g. truck, bus, train, or 
aircraft)? 
5. Prior to 2010, FAA regulation stated that pilots diagnosed with an anxiety and/or 
depressive disorders were prohibited from exercising the privileges of Pilot in 
Command and obtaining a medical certificate.  This also applied to those who may be 
taking medication as a treatment option for this disorder.  In your professional 
opinion was this regulation adequate?
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6. In 2010, the FAA changed their certification standards regarding anxiety, depression, 
and treatment options.  An applicant may be able to act as Pilot in Command and 
receive a medical waiver if one were to use an approved FAA medication.  
Certification required an applicant to show demonstrated use of the medication under 
supervision of a psychiatric care physician for a period of twelve months.  After 
twelve months an applicant may request a re-evaluation of their medical application 
by the FAA.  An application could be approved or denied.  In your professional 
opinion, was this an adequate certification process? 
7. In 2015, the FAA changed their certification standards regarding anxiety, depression, 
and treatment options.  An applicant may be able to act as Pilot in Command and 
receive a medical waiver if one were to use an approved FAA medication.  
Certification required an applicant to show demonstrated use of the medication under 
supervision of a psychiatric care physician.  The demonstrated time frame was 
reduced from twelve to six months.  After six months an applicant may request a re-
evaluation of their medical application by the FAA.  An application could be 
approved or denied.  In your professional opinion, is this an adequate certification 
process? 
8. As early as the 1980s, some ICAO States have allowed their pilots to use various 
medications to treat anxiety and/or depressive disorders.  Australia for example is one 
of these States.  Australia has a certification process that takes no more than thirty 
days.  Moreover, the Australian Aviation Authority has concluded that individuals 
taking medication for anxiety and/or depressive disorders are no more dangerous than 
those who have not been diagnosed with, nor suffer from, anxiety and/or depression.  
Other ICAO States share a similar opinion with Australia regarding the certification 
process.  Based on this information, when comparing it to how the FAA certifies U.S. 
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1. According to articles written, the FAA has relaxed their requirements from a twelve-
month certification process to six months for those suffering from anxiety and/or 
depressive disorders, and/or taking an SSRI.  What was the basis for shortening the 
certification time? Does the FAA believe this time-frame is adequate, too relaxed, or 
too stringent?  The basis for the determination was scoping in on the history of ‘mild 
depression’ and determining that no other medical or psychiatric conditions were 
present. And that current medication treatment was adequate. The time frame 
specified has been adequate.  This interval of time provided more flexibility in less 
severe depression cases.  
2. Prior to 2010, the FAA did not allow pilots to exercise privileges of an airman 
certificate and medical if one was diagnosed with a anxiety, depression, and/or taking 
an SSRI.  Why did the FAA make the decision to change its view on the subject? The 
FAA medical officers and FAA psychiatrist determined, that based on case reports 
and personal clinical experience that the psychiatric condition and use of  acceptable 
medications that had a low side-effect profile would not impact the safety of the 
National Airspace System. 
3. When the FAA makes the determination to change a policy on a subject, such as 
anxiety and depressive disorders, what information does the FAA consider prior to 
making its decision? The FAA Aerospace Medicine program is science based that 
relies upon evidence base medical literature and clinical experience to make its 
medical/managements decisions. We also rely upon consultant reviews and the 
national data base of aircraft accidents to validate our medical determinations. 
4. Currently the FAA has only approved four SSRI medications: (1) Lexapro; (2) 
Prozac; (3) Celexa; and (4) Zoloft.  There are many other SSRIs on the market such 
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as Paxil, NDRIs such as Wellbutrin, SNRIs such as Cymbalta, or some next 
generation mediations such as Buspar.  Why have only the first four medications 
received approval by the FAA?  What options are available for an applicant if one of 
the four approved SSRIs are not an effective treatment option? The diagnosis and 
medications we determined could be used by aviators all are low risks conditions. 
And the medications approved have the lowest possible side-effect profile. We are 
not considering any other antidepressant medications at this time. 
5. Once an applicant has successfully met the certification requirement and 
demonstrated acceptable usage of an SSRI the Federal Air Surgeon may then, at their 
discretion, issue a waiver allowing for the issuance of a medical certificate to an 
applicant.  What are the primary reasons for declining a waiver even if the applicant 
has successfully met all the initial requirements? The essence of a denial of an FAA 
airman medical certificate is based upon clinical review of the psychiatric history. If 
the individual under consideration does not meet the FAA published requirements or 
the approved psychiatric medication was discontinued that is not clinically explained 
and other psychiatric conditions or medical conditions are present, then the applicant 
will be denied. 
6. What is the FAA doing to ensure that all certificated pilots in the U.S. comply with 
the required regulations regarding anxiety, depression, and SSRIs? There is an active 
program that is managed by FAA Aerospace Medicine SSRI program medical 
personnel. The underpinnings of the program include educating the FAA Aviation 
Medical Examiners who are the first representatives of the FAA that interact with 
aviators. The reporting requirement stipulated in the program are published and clear. 
The information is provided in real time and medical determinations are made in real 
time. The overall process is always under review using QMS/SMS processes 
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7. Does the FAA have estimates of how many U.S. pilots are not complying with the 
required regulations regarding anxiety, depression, and SSRIs? We have no way of 
determining who is not complying with the program. However, after 7 years we have 
500 aviators who have participated in the program. We acknowledge that this is a 
fraction of the aviator population who most likely are flying with the condition and 
medications without our knowledge. 
8. The Australian Civil Aviation Safety Authority has concluded that individuals taking 
medication for anxiety and/or depressive disorders are no more dangerous than those 
who have not been diagnosed with, nor suffer from, one of these disorders.  Does the 
FAA agree with this statement? The FAA Aerospace Medicine managers do not 
agree with the Australian CAA. We would not be granting special issuance medical 
certificates if we did not believe that the risk was close to that of the unaffected 
population. 
9. When comparing FAA pilot certification standards for anxiety, depression, and/or 
SSRI use to those of ICAO, or ICAO states, does the FAA find that ICAO and/or 
ICAO State standards to be less effective or less restrictive than theirs? We have not 
evaluated their process. 
10. Any additional comments? We have collaborated with the ICAO prior to adopting 
our current policy. This collaboration has led to ICAO adopting a recommended 
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Swedish Transport Agency Email Communications and Responses to Interview/Survey 
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Dr. Lacy Anderson: Email Communications and Responses to Interview/Survey Questions 
























































FAA SSRI Pathway Guidance for Aviation Medical Examiners (AMEs) 
 






















FAA SSRI Initial Certification Aid 
 









































Hamilton Depression Scale 
 
Figure 13.  Hamilton Depression Scale (Reproduced from Hamilton, 1960). 
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Professional Pilot Forum Survey Invitation Views 
 













Data Results from SurveyMonkey 
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